Detection of novel nucleic acid markers in bodily fluids. by Shing, Ka Fai. & Chinese University of Hong Kong Graduate School. Division of Chemical Pathology.
Detection of Novel Nucleic Acid Markers in 
Bodily Fluids 
SHINQ Ka Fai 
A Thesis Submitted in Partial Fulfilment 
of the Requirements for the Degree of 
Master of Philosophy 
in 
Chemical Pathology 
© The Chinese University of Hong Kong 
August 2007 
The Chinese University of Hong Kong holds the copyright of this thesis. Any 
person(s) intending to use a part or whole of the materials in the thesis in a 
proposed publication must seek copyright release from the Dean of the 
Graduate School 
H 0 2 SEP 2i ) i | 
^^^瞧RY SYSTEM 
ABSTRACT 
DETECTION OF NOVEL NUCLEIC ACID MARKERS IN 
BODILY FLUIDS 
Submitted by SHING Ka Fai for the degree of Master of Philosophy in Chemical 
Pathology at the Chinese University of Hong Kong in August 2007 
The presence of cell-free nucleic acids in bodily fluids of humans has been described 
for decades. Recent technological advances have opened up numerous possibilities 
for noninvasive molecular analyses. This thesis aimed at exploring the biology and 
diagnostic potentials of a novel class of circulating nucleic acid, microRNAs 
(miRNAs), in the plasma of pregnant women and also of transrenal DNA (Tr-DNA) 
in the urine of patients undergoing hematopoietic stem cell transplantation (HSCT). 
Previously, no data have been published on the presence of miRNAs in human 
plasma. The first part of this thesis aimed to develop a quantitative method for 
analyzing cell-free miRNA in plasma. Because miRNAs are very short, with only 
21-25 nucleotides, extraction of circulating miRNA was performed using a modified 
extraction protocol which can efficiently retain the small RNA fraction. Moreover, 
the quantification of miRNAs was performed using the Taqman® MicroRNA Assays 
(Applied Biosystems) which employ stem-loop primers to reverse transcribe the 
short miRNAs into longer cDNA molecules. Using these specifically designed 
extraction and detection methods, I demonstrated, for the first time, the presence of 
high concentration of cell-free miRNA in maternal plasma. These findings have laid 
the foundation for the development of circulating miRNAs as a class of markers for 
noninvasive monitoring. 
i 
The second part of this thesis was aimed at systematically identifying a list of 
placental miRNAs potentially detectable in maternal plasma during pregnancy. The 
levels of 157 miRNAs were systematically analyzed. MiRNAs expressed at much 
higher levels in the placenta than maternal blood cells, but not detectable in maternal 
plasma after delivery were identified. Using this approach, I identified the placental 
miRNAs miR-141 and miR-149. The temporal profile of one placental miRNA in 
maternal plasma across different trimesters was also studied. To further decipher the 
physical natures of placental miRNAs, maternal plasma was passed through filters 
and quantified for miRNA. No change in miRNA concentration was observed after 
filtration. Moreover, naked, purified miRNA molecules showed a slower degradation 
than purified messenger RNA when incubated in plasma and were still detectable for 
up to 2 hours. This part of the thesis has unveiled placental miRNA in maternal 
plasma as a novel class of circulating nucleic acids with potential for noninvasive 
prenatal monitoring. 
In the third part of this thesis, I analyzed cell-free DNA in urine using a 
sex-mismatched HSCT model. With a newly devised MassEXTEND™ assay 
accurately quantifying the fractional concentration of donor-derived DNA and 
quantitative PGR assays studying DNA size distribution, I discovered that a 
considerable fraction of donor-derived DNA and also another fraction of 
high-molecular weight DNA originated from cells, probably shed from the urinary 
tract, in the cell-free urinary DNA of patients undergoing sex-mismatched HSCT. 
Such findings would enlighten investigators in this field on the further development 
of better molecular assays targeting these DNA fractions in urine for different 
noninvasive diagnostic purposes. 
ii 
The results presented in this thesis have not only increased the current understanding 
on miRNA in plasma and cell-free DNA in urine, but have also laid the ground work 
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SECTION I: BACKGROUND 
1 
Cell-free nucleic acids in human bodily fluids 
CHAPTER 1: CELL-FREE NUCLEIC ACIDS IN HUMAN 
BODILY FLUIDS 
1.1 Early studies on the presence of cell-free nucleic acids in human bodily fluids 
In as early as the mid century, Mandel and Metais (1948) were the first to 
measure and compare the levels of nucleic acids in the plasma of patients and healthy 
persons. This was the first documentation of the existence of cell-free nucleic acids 
in human bodily fluids. However, few studies continued to pursue on the presence 
and applications of cell-free nucleic acids in human bodily fluids until the late 1960s, 
when Tan et al (1966) showed that in patients with systemic lupus erythematosus, 
there was an elevated level of circulating DNA in serum. In the following decades, 
the clinical values of circulating nucleic acids gradually emerged. The presence of 
plasma/serum DNA was demonstrated in rheumatoid arthritis (Koffler et al 1973, 
Leon et al. 1977a), pulmonary embolism (Barada et al 1980) and hemodialysis 
(Steinman and Ackad 1977). 
Besides plasma and serum, cell-free DNA was also reported to be present in other 
human bodily fluids such as urine (Botezatu et al 2000), amniotic fluid (Bianchi et 
al 2001), cerebrospinal fluid (Angert et al. 2004), and peritoneal fluid (Cioni et al 
2003). These findings, together with the numerous technological advances, have 
triggered a growing tide of interest in the study of cell-free nucleic acids in human 
bodily fluids as a potential molecular tool for molecular analyses. 
1.2 Circulating nucleic acids in plasma and serum 
Cell-free circulating nucleic acids in plasma/serum are noninvasive sources of 
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genetic material for applications in molecular tests. They can be easily accessed with 
the collection of peripheral blood samples. Potential applications of these genetic 
materials were also made possible with technologically advances, e.g. real-time 
quantitative polymerase chain reaction (PCR) and reverse transcriptase (RT)-PCR. 
Together, they have provided important future venues for noninvasive cancer 
detection and prenatal diagnosis. 
1.2.1 Cancer Detection 
The detection of cell-free tumor-derived nucleic acids in the circulation provides a 
convenient and noninvasive approach for cancer diagnosis. Conventional diagnostic 
and assessment methods for cancer detection have a number of drawbacks. For 
example, when collecting cells and biopsies for cytological and histological analyses, 
such as the Papanicolao smear and colonoscopy, the invasive procedures may result 
in traumatic or discomforting effects on the patients. Other assessment techniques, 
such as computed tomography (CT) and magnetic resonance imaging, are 
noninvasive but are so expensive that it limits their applications as screening tests. 
Thus, there is an increasing need for the development of noninvasive approaches for 
cancer detection. This is facilitated with the discovery of circulating tumor-derived 
nucleic acids. 
1.2.1.1 Circulating tumor-derived DNA 
Early studies demonstrated increased levels of cell-free DNA in plasma/serum of 
patients with different malignancies (Leon et al 1977b, Shapiro et al 1983, Stroun et 
al. 1987). Of particular interest, the levels of cell-free DNA in the serum of patients 
with metastases were higher than those without metastases (Leon et al. 1977b); 
treated patients with higher plasma/serum levels of cell-free DNA were associated 
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with a poor prognosis (Leon et al 1977b). Although these early studies did not 
address the identity of the tumor-derived DNA, they suggested that circulating 
cell-free DNA in plasma/serum could play a role in cancer detection and monitoring. 
Since then, the development of sequence-specific DNA detection techniques, e.g. the 
PCR, has further catalyzed the use of cell-free DNA in plasma/serum for cancer 
detection. Different types of tumor-derived mutated DNA sequences were identified 
in the plasma/serum of cancer patients. These include, firstly, oncogenes, such as the 
Ras mutation, in the plasma/serum of patients with pancreatic cancer (Mulcahy et al. 
1998, Yamada et al 1998, Castells et al 1999, Theodor et al. 1999), colorectal 
cancer (Anker et al 1997, de Kok et al 1997, Kopreski et al 1997，Hibi et al. 1998), 
and myelodysplastic syndrome or acute myelogenous leukemia (Vasioukhin et al. 
1994). Second, mutated sequences of tumor suppressor genes, e.g. mutated p53 
sequence, in patients with hepatocellular carcinoma (Kirk et al 2000) and large 
bowel cancer (Mayall et al 1998). Third, DNA sequences with microsatellite 
alterations in patients diagnosed with primary head and neck squamous cell 
carcinoma (Nawroz et al. 1996) and small cell lung cancer (Chen et al 1996). Fourth, 
hypermethylated promoter DNA sequences in patients with breast cancer (Hoque et 
al. 2006), colorectal cancer (Bazan et al 2006), liver cancer (Wong et al. 1999)， 
lymphoma (Deligezer et al 2003), cervical cancer (Yang et al 2004), and melanoma 
(Marini et al. 2006). Finally, DNA sequences of different tumor-associated virus 
were also found in cancer patients (Mutirangura et al 1998, Gallagher et al 1999, 
Capone et al. 2000, Pomthanakasem et al. 2001). The successful detection of the 
various tumor-derived DNA sequences in the plasma/serum of cancer patients has 
established the foundation for the noninvasive detection of cancers. 
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Of significant interest, circulating tumor-derived DNA has several advantages over 
the more traditional cancer detection methods. For example, plasma DNA markers 
are potentially applicable for early cancer diagnosis and screening (Eisenberger et al 
2006). Subsequent studies have also revealed their potentials in prognostication 
(Castells et al. 1999，Kawakami et al 2000，Lo et al 2000a, Taback et al. 2001, 
Gautschi et al. 2004), disease recurrence (Lo et al. 1999b, Gonzalgo et al. 2002, 
Ryan et al 2003)，and treatment outcome (Lo et al. 2000b, Kimura et al. 2004, 
Taback et al. 2004). In brief, circulating tumor-derived DNA has enabled a new class 
of noninvasive markers with unprecedented advantages over the more traditional 
cancer detection methods. 
1.2.1.2 Circulating tumor-derived RNA 
Although circulating tumor-derived DNA exhibits overwhelming potentials for 
developing noninvasive cancer detection methods, researchers in the field have been 
in constant search for another type of nucleic acid, that is circulating tumor-derived 
messenger RNA (mRNA), for cancer detection. The detection of circulating 
tumor-derived mRNA has several advantages in terms of higher sensitivity and 
specificity. First, each single cell possesses multiple copies of mRNA, as compared 
with one genome equivalent of DNA copies. Second, expression of mRNA can be 
tumor-, tissue- or even cell-specific. Therefore, the detection of these mRNA in 
plasma not only opens up the possibility for highly sensitive noninvasive cancer 
detection, it may also enable the development of tailor-made approaches to 
monitoring of cancer progression. 
Using the RT-PCR，Kopreski et al. (1999) and Lo et al. (1999a) were the first to 
report the presence of tumor-derived mRNA in the serum and plasma of cancer 
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patients, respectively. In particular, Kopreski et al. (1999) showed that the 
tumor-derived TYR mRNA detected in serum was free from contaminating tumor 
cells, i.e. they are cell-free. The presence of cell-free mRNA in the plasma/serum is 
surprising given the lability of RNA and the elevated level of serum RNases in 
cancer patients (Reddi and Holland 1976). Subsequent studies were able to detect, in 
plasma/serum of cancer patients, candidate mRNA transcripts that are frequently 
expressed in tumor tissues. They include different telomerase components (Chen et 
al 2001b, Dasi et al 2001, Miura et al. 2003, Novakovic et al 2004), 
epithelial-expressed genes (Gal et al 2001, Silva et al. 2001, Silva et al 2002, 
Kijima et al 2005), and beta-catenin (Wong et al 2004b). In particular, Miura et al. 
(2003) reported that the detection of serum TERT mRNA was more sensitive than 
either ce-fetoprotein {AFP) or AFP mRNA alone in the diagnosis of hepatocellular 
carcinoma. These results demonstrated some of the advantages of circulating 
tumor-derived mRNA measurements over conventional diagnostic tumor markers. 
In recent years, the use of real-time quantitative RT-PCR has extended the scope and 
enabled the use of quantitative aberrations in circulating mRNA for cancer detection. 
Dasi et al. (2001) were the first to report that the plasma TERT mRNA levels were 
7-fold and 10-fold higher in patients with colorectal cancer and follicular lymphoma, 
respectively, than in healthy controls. In contrast, there were no significant 
differences in TERT mRNA expression in the corresponding cells of the cancer 
patients and healthy controls. Taken together, these findings reinforced the clinical 
significance of plasma-based molecular analysis in cancer diagnosis. Subsequent 
studies also established the diagnostic use of the quantification of circulating 
tumor-derived mRNA in lung (Sueoka et al. 2005, Pelosi et al 2006) and liver 
cancers (Miura et al. 2003). 
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1.2.2 Prenatal diagnosis 
Conventional prenatal diagnoses and assessments have a number of drawbacks. For 
example, they usually involve the use of invasive techniques such as amniocentesis 
and chorionic villus sampling. These invasive methods impose a definite risk of 
miscarriage. In addition, noninvasive prenatal assessment techniques, such as 
biochemical screening and ultrasound scanning, are associated with a significant 
false positive rate. Thus, there is a long-standing need for a platform technology for 
definitive and reliable noninvasive prenatal diagnosis. 
Inspired by the “pseudomalignant，，nature of the human placenta (Strickland and 
Richards 1992), researchers demonstrated the existence of circulating cell-free fetal 
DNA and mRNA in pregnant women as in the release of circulating tumor-derived 
nucleic acids in cancer patients (Lo et al. 1997, Poon et al. 2000). Since then, these 
circulating fetal nucleic acids have provided new possibilities for noninvasive 
prenatal diagnosis. In addition, the recent discovery of microRNA (miRNA), which 
has important roles in gene regulation, in placental tissues (Barad et al. 2004, 
Bentwich et al 2005), has raised questions of whether this class of small non-coding 
RNA can be developed as another novel class of markers. 
1.2.2.1 Circulating fetal DNA 
Using a Y-chromosome-specific PCR assay, the existence of fetal DNA in maternal 
plasma/serum was first confirmed in women conceived with male fetuses (Lo et al 
1997). In a subsequent study, the same group developed a real-time quantitative PCR 
assay targeting a gene, the sex-determining region Y {SRY), on the Y chromosome to 
determine the fractional concentration of fetal DNA in maternal plasma (Lo et al. 
1998b). It was found that fetal DNA constituted a mean percentage of 3.4% and 6.2% 
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in maternal plasma in early and late pregnancies, respectively. Comparing with fetal 
DNA constitutions, arising from fetal cells, of 0.0035% and 0.008% in the second 
and third trimesters of pregnancy (Hamada et al. 1993), respectively, these results 
demonstrated the significant enrichment of the extracellular fetal DNA in maternal 
plasma and the robustness of the detection. Besides, it was found that there was a 
rapid clearance of circulating fetal DNA after delivery (Lo et al 1999e), which 
suggested that fetal DNA from previous pregnancies will not persist until subsequent 
ones. In addition, studies showed that fetal DNA could be reliably detected in 
maternal plasma/serum from as early as the fifth week of gestation (Honda et al 
2002, Rijnders et al 2003). In pregnant women conceived with assisted reproduction, 
it was shown that fetal DNA appears in maternal plasma from as early as the 1S^ ^ day 
after embryo transfer (Guibert et al. 2003). These findings demonstrated the 
feasibility of using circulating fetal DNA for noninvasive prenatal diagnosis from as 
early as the first trimester. 
Fetal gender determination 
The initial discovery of circulating Y-chromosome-specific sequences in maternal 
plasma (Lo et al. 1997) inspired the use of the technique for fetal gender 
determination. Subsequent studies reported that such assessment of fetal gender by 
plasma DNA is both sensitive and specific (Costa et al 2001, Sekizawa et al. 2001a, 
Wei et al 2001, Zhong et al. 2001b). This highly accurate method was useful for risk 
stratifying families at risk of sex-linked disorders to appropriate clinical management 
(Costa et al. 2002a). This application was proven useful in management of pregnancy 
at risk of congenital adrenal hyperplasia (Rijnders et al. 2001). 
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Prenatal exclusion of fetal genetic diseases 
In maternal plasma, cell-free DNA arises from both maternal and fetal sources. 
Unlike maternally-inherited fetal DNA which is indistinguishable from the high 
background of maternal plasma DNA, paternally-inherited fetal DNA is 
distinguishable from maternal DNA using polymorphic sites, such as mutated or 
short tandem repeat (STR) sequences. Therefore, most studies on the uses of 
circulating fetal DNA focused on paternally-inherited fetal DNA. 
Detection of mutations in certain autosomal dominant diseases in maternal plasma 
was a commonly studied application. For example, the detection of expanded CTG 
trinucleotide repeats in the dystrophia myotonica protein kinase gene in maternal 
plasma was shown to be informative for the prenatal exclusion of myotonic 
dystrophy (Amicucci et al 2000). Subsequent reports also demonstrated the use of 
circulating fetal DNA for the prenatal exclusion of autosomal recessive diseases, 
such as Huntington disease (Gonzalez-Gonzalez et al 2003), cystic fibrosis 
(Gonzalez-Gonzalez et al. 2002), (3-thalassemia major (Chiu et al 2002b), and other 
hemoglobinopathies (Fucharoen et al 2003). However, the application in these cases 
is more complicated because the mere presence of a recessive allele cannot confirm 
or exclude the inheritance of the diseases. In light of this problem, Chiu et al. (2002a) 
have demonstrated the feasibility of prenatal exclusion of congenital adrenal 
hyperplasia using paternally-inherited non-mutant polymorphic markers in fetal 
DNA. 
Several research groups also reported the feasible use of circulating fetal DNA as a 
tool to monitor fetal aneuploidies. For example, Chen et al, (2000, 2001a) 
demonstrated that STR sequences in circulating fetal DNA can be used for diagnosis 
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of paternally-inherited fetal aneuploidies. In particular, quantitative aberrations of 
circulating fetal DNA can also aid the screening of fetal aneuploidies. For example, 
Lo et al. (1999c) and Lee et al (2002a) reported that in pregnant women conceived 
with fetuses with Down syndrome (trisomy 21), the plasma and serum level of fetal 
DNA has a 2-fold and 1.7 fold, respectively, increase compared with fetal gender and 
gestational age matched healthy pregnant women. Moreover, when analyzed in 
conjunction with the quadruple test from routine biochemical screening, fetal DNA 
can improve the detection rate from 81% to 86% at a 5% false-positive rate (Farina et 
al. 2003). Increased level of fetal DNA in maternal plasma was also demonstrated in 
pregnancies affected by trisomy 13 (Wataganara et al 2003). However, there is no 
screening marker available for the detection of trisomy 13 at present. Moreover, 
using epigenetic allelic ratio (EAR) analysis of the maspin gene, Tong et al. (2006) 
successfully demonstrated the noninvasive prenatal analysis of of trisomy 18. 
Indication of fetomaternal well-beins 
Rhesus D-negative pregnant women with rhesus D-positive fetuses carry an inherent 
risk of hemolytic disease of the newborn (HDN) as a result of alloimmunization. 
Faas et al. (1998) and Lo et al. (1998a) were the first to demonstrated the use of 
circulating fetal DNA for the prenatal analysis of fetal rhesus D status, which 
provides information for appropriate clinical management. As HDN is more severe in 
male fetuses (Ulm et al. 1998, Ulm et al 1999), subsequent establishment of 
multiplex real-time PCR assay by Zhong et al. (2001c) for fetal gender and rhesus D 
status determination further facilitated such a clinical application. Costa et al. (2002b) 
later showed that circulating fetal DNA was highly reliable in rhesus D status 
determination. Because the noninvasive fetal RHD genotyping is accurate and has 
10 
Cell-free nucleic acids in human bodily fluids 
lower associated costs, it has become a noninvasive molecular prenatal diagnostic 
test to be adopted routinely in the United Kingdom, France, and the Netherlands 
(Finning et al. 2002，Dee et al 2003, Bianchi et al 2005). 
Using quantitative real-time PGR assays, several studies reported quantitative 
aberrations of circulating fetal DNA in the plasma/serum of women with pathological 
pregnancies, e.g. preterm delivery (Farina et al 2005), polydramnios (Zhong et al. 
2000), fetomatemal hemorrhage (Lau et al. 2000, Samura et al. 2003), hyperemesis 
gravidarum (Sekizawa et al. 2001b), and invasive placentation (Sekizawa et al. 
2002). In particular, in pregnant women with preeclampsia, the levels of circulating 
fetal DNA were elevated compared with those in normal pregnant women (Lo et al. 
1999d, Smid et al. 2001, Shimada et al 2004). The levels also correlate with disease 
severity (Zhong et al 200le) and clinical onset (Leung et al 2001). 
1.2.2.2 Circulating fetal messenger RNA 
Subsequent to the discovery of circulating tumor-derived mRNA in cancer patients 
(Kopreski et al. 1999), Poon et al. (2000) were the first to demonstrate the presence 
of fetal-specific mRNA in the plasma of pregnant women. The potential use of 
circulating fetal mRNA for prenatal diagnosis has several advantages over the use of 
circulating fetal DNA. First, as in tumor-derived mRNA, the much higher copy 
number of mRNA than genomic DNA per cell may offer higher sensitivity and 
specificity of detection. Second, the detection and identification of circulating fetal 
mRNA offer the possibility to overcome the limitation to using gender or genetic 
polymorphism differences between the mother and the fetus. Moreover, circulating 
fetal RNA is detectable from as early as the fourth week of gestation (Chiu et al. 
2006). This suggested the potential of circulating fetal mRNA for early prenatal 
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analysis. Hence, circulating fetal mRNA offers significant potential for the 
development of new molecular markers for noninvasive prenatal diagnosis. 
Circulating placental mRNAs display a number of physical characteristics. For 
example, Ng et al (2003b) demonstrated the association of placental mRNAs in 
plasma with subcellular particles. It was suggested that these placental mRNAs were 
possibly associated with syncytiotrophoblast microparticles (Gupta et al. 2004). 
Moreover, it was shown that placental mRNAs in the maternal plasma appeared to 
have a preponderance in the 5' end of the fragments (Wong et al 2005). 
Speculation has been placed on the placental origin of circulating fetal mRNA. Poon 
et al. (2000) were the first to demonstrated the presence of fetal-specific Y-linked 
zinc finger protein gene mRNA in maternal plasma. Using real-time quantitative 
RT-PCR assays, the same group demonstrated the presence of two mRNA transcripts, 
human placental lactogen QiPL) mRNA and the beta subunit mRNA of human 
chorionic gonadotropin (fihCG) which were specifically expressed in placenta, in 
maternal plasma (Ng et al 2003b). Subsequent studies were conducted to increase 
the number of circulating fetal mRNA transcripts available for use in noninvasive 
prenatal diagnosis. For example, Go et al. (2004) screened a panel of potential 
mRNA transcripts expressed in extraembryonic tissues and demonstrated the 
detection of placental transcription factor mRNA in maternal circulation. Moreover, 
Tsui et al (2004) used a systematic and high throughput oligonucleotide microarray 
approach to identify a number of circulating fetal mRNA transcripts. All of these 
transcripts showed rapid clearance in maternal circulation which suggested the 
pregnancy-specificity of their presence and indicated their clinical potentials as 
noninvasive fetal-specific markers. 
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Studies were also conducted to demonstrate the association of pathological 
pregnancies with quantitative aberration of these circulating fetal mRNAs. For 
example, circulating mRNA transcript of corticotropin-releasing hormone {CRH) was 
shown to be 10-fold elevated in plasma collected from preeclamptic pregnancies 
when compared with control cases (Ng et al. 2003a). Masuzaki et al (2005) 
suggested that the measurement of plasma mRNA by real-time quantitative RT-PCR 
can be used as a noninvasive diagnostic, prognostic, and follow-up test for 
gestational trophoblastic disease. In women carrying trisomy 18 fetuses, the serum 
concentration of phCG mRNA was 9.4-fold lower than that in normal pregnant 
women (Ng et al. 2004). The presence of chromosome 21-encoded mRNA of 
placental origin in the plasma of women between the and weeks of pregnancy 
demonstrated potential for the early prenatal screening of Down syndrome (Oudejans 
et al 2003). Using mass spectrometry, Lo et al (2007) demonstrated the use of 
plasma placental RNA ratio in prenatal diagnosis of fetal trisomy 21. Taken together, 
these studies demonstrated feasibilities of circulating fetal mRNA for noninvasive 
prenatal diagnosis. 
1.2.2.3 Circulating placental microRNA 
MicroRNAs (miRNAs) are a family of small (21-25 nucleotides), non-coding RNAs 
that negatively regulate gene expression at the post-transcriptional level (Ambros 
2003, Lai 2003, Battel 2004). At the time of this writing, no data have been 
published in relation to the presence of cell-free miRNA in the plasma of humans. 
Interestingly, Barad et al. and Bentwich et al (2004, 2005) have shown the presence 
of placental-specific miRNAs in human. This has raised the question of whether such 
small non-coding RNA can indeed be detected in maternal plasma as markers for the 
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noninvasive prenatal diagnosis as in the detection of placental mRNA. 
MiRNAs are associated with various regulatory functions in humans (Bartel 2004). 
Moreover, they exist at much higher copy numbers in cells than mRNAs (Lim et al. 
2003). Therefore, they have potential to be developed as highly sensitive prenatal 
diagnostic markers in maternal plasma. However, considerable challenges have 
hampered such potential use of miRNA. First, the rich protein content of plasma has 
posed difficulties for efficient RNA extraction. Second, most column-based protocols 
for RNA extraction result in great loss of short RNA molecules, which were 
previously considered as “contaminants” to the longer mRNA molecules. Third, 
special PCR techniques are required to specifically and sensitively detect these short 
RNA molecules. Fourth, over 400 human miRNA species have been identified 
(Griffiths-Jones 2004), but only a minor proportion of them has been studied in detail. 
Insights into the roles and hence their potential use as diagnostic miRNAs were 
lacking. It would be one of the major objectives of this thesis to investigating the 
possibility of developing miRNAs as novel markers for noninvasive prenatal 
diagnosis. In Chapter 2, detailed description of the biology of microRNA in humans 
is provided. 
1.3 Cell-free nucleic acids in urine 
The presence of cell-free DNA in urine offers another novel and completely 
noninvasive source of genetic materials for clinical analysis. In recent years, same 
interest has been focused on the study of transrenal DNA (Tr-DNA), which is 
cell-free DNA in urine derived from circulating cell-free DNA in plasma as it passes 
through the kidney barrier (Botezatu et al 2000). It is distinct from the high 
-molecular weight cell-free DNA in urine which is released from cells shed along the 
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urinary tract. For this latter scenario, passage of DNA through the kidney barrier is 
not involved. The postulated plasma sources of Tr-DNA suggested its origin from 
throughout the body, which offers a potentially new diagnostic tool with attractive 
utility (Umansky and Tomei 2006). 
1.3.1 Transrenal DNA (Tr-DNA) 
1.3.1.1 Biology of Tr-DNA 
Botezatu et al (2000) was the first to demonstrated the existence of Tr-DNA in 
humans. In brief, this group showed that male-specific sequences could be detected 
in the urine of women pregnant with male fetuses. Furthermore, K-ras mutations 
associated with colon adenocarcinoma could be detected in the urine of the cancer 
patients. In addition, Su et al (2004b) showed that Tr-DNA has a length between 150 
and 250 bp. They also reported technical refinements, including DNA extraction 
method and PGR assay design (e.g. amplicon size), which would enhance the 
detection of such Tr-DNA species (Su et al 2004a). 
Several mechanisms through which DNA may be able to pass through the kidney 
barrier were postulated (Lichtenstein et al. 2001, Umansky and Tomei 2006). There 
were three major hypotheses: (a) Tr-DNA having a size which is below the 
glomerular filtration cutoff of 65 kDa; (b) the use of large shuntlike pores in the 
kidney with the involvement of serum amyloid P component on the secondary 
structure of DNA, and (c) the passage of DNA contained inside liposome-like 
particles. However, the true mechanism behind remains to be elucidated. 
1.3.1.2 Detection of fetal-derived Tr-DNA 
Several groups have investigated the possibility of detecting transrenal fetal DNA. 
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As in plasma where circulating maternally-derived fetal DNA is indistinguishable 
from maternal cell-free DNA, detection of fetal Tr-DNA depends on gender and 
genetic DNA polymorphism for its distinction from maternal cell-free DNA in urine, 
e.g. Y chromosome sequences of male fetuses. Using Y chromosome specific PCR, 
the initial detection of fetal derived Tr-DNA was reported by Botezatu et al. (2000). 
Subsequent studies reported that the detection of fetal DNA in urine can be achieved 
from as early as the seventh week of gestation (Al-Yatama et al 2001). These 
findings suggested that urine Tr-DNA is a novel class of nucleic acids potentially 
applicable for noninvasive prenatal diagnosis in as early as the first trimester. Using 
quantitative real-time PCR assays, Koide et al. (2005) have shown that fetal-derived 
Tr-DNA was more readily detectable with PCR amplicon of less than 107 bp. This 
has provided further technical consideration for the molecular analysis of Tr-DNA. 
However, not all workers in the field are convinced with the reliability of detecting 
fetal-derived Tr-DNA. For example, Zhong et al. (2001a) reported inability to detect 
male-specific DNA in urine samples obtained from women pregnant with male 
fetuses. In particular, in a cohort of pregnant women suffering from pre-eclampsia, 
the same group was again unable to detect such fetal-derived Tr-DNA (Li et al. 2003). 
This is especially remarkable because pregnant women with pre-eclampsia have 
elevated levels of circulating fetal DNA (Zhong et al 200Id) and increased renal 
permeability, as evidenced by proteinuria (Hayashi et al. 2002). 
1.3.1.3 Potential problems associated with the detection of Tr-DNA 
In addition to the fact that Tr-DNA was reported to be detectable by some but not all 
investigators in this field, considerable challenges have hampered such potential use 
of Tr-DNA. First, there is currently no consensus method for the processing, 
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extraction and detection of cell-free DNA from urine. As a result, fair comparisons of 
results and conclusion cannot be produced between research groups. Moreover, an 
accurate analytical system for quantifying the fractional concentration of Tr-DNA in 
urine is lacking. In turn, such a lack of accurate quantification methods has also 
impaired the development of better urine DNA extraction protocols. Therefore, it is 
one of the major objectives of this thesis to evaluate the possibility of Tr-DNA 
analysis in a sex-mismatched hematopoietic stem cell transplantation (HSCT) system. 
This model has a higher fractional concentration of donor-derived DNA in plasma 
than fetal DNA has in maternal plasma. Thus, more donor-derived DNA is expected 
to pass into the urine and may allow more robust detection. The implementation of 
this HSCT model has the potential to greatly improve current understanding of the 
phenomenon of Tr-DNA. It is hopeful that the use of this HSCT model has several 
advantages over other models being used previously. This fractional concentration of 
donor-derived DNA in HSCT recipients (Lui et al 2002) is much higher than the 
mean fractional concentration of fetal DNA in maternal plasma, which is only 3.4% 
during weeks 11 to 17 of gestation and 6.2% in the third trimester of pregnancy (Lo 
et al 1998b), and less variable than that of tumor in the plasma of cancer patients 
(Anker et al 1997). Thus, these results suggested that sex-mismatched HSCT may be 
a more powerful model system for the investigation on Tr-DNA because 
donor-derived DNA might be more readily detected in the urine of the HSCT 
recipients than in other transrenal models. 
1.3.2 Cell-free DNA in urine as released from the urinary tract 
Cell-free DNA released from the urinary tract has two main channels to enter the 
urine. First, cells shed from the urinary tract may contribute to the high-molecular 
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weight cell-free DNA in urine upon cell death. Second, DNA enters the circulation as 
circulating cell-free DNA which then appears as Tr-DNA. In normal individuals, not 
much can be done to distinguish the two. However, these two scenarios may be 
distinguished in special clinical scenarios. 
As a demonstration of the shedding of urinary tract DNA into urine, Eisenberger et al. 
(1999) reported the detection of tumor-derived DNA in the urine of renal cancer 
patients. Tumor-derived DNA was also detectable in the urine and corresponding 
plasma/serum of patients suffering from prostate carcinoma (Goessl et al 2000, 
Jeronimo et al. 2002) and bladder cancer (Utting et al. 2001). 
As another example of the shedding of urinary tract DNA into urine, using real-time 
quantitative PCR assay for Y-chromosome sequences, donor-derived male DNA was 
also detectable in the urine of female recipients of renal transplants (Zhang et al. 
1999). Elevated level of urinary DNA was observed during an acute rejection episode. 
Subsequent to anti-rejection treatment, it showed that the DNA level rapidly returned 
to a normal level (Zhang et al. 1999). This illustrated the potential use of cell-free 
DNA in urine for organ transplant monitoring. 
1.4 Other bodily fluids with cell-free nucleic acids 
Cell-free DNA and RNA were also detected in bodily fuilds other than plasma, serum 
and urine. They include amniotic fluid, cerebrospinal fluid, and peritoneal fluid. This 
section gives a brief summary of recent progresses in this field. However, it should 
be noted that the sampling of these bodily fluids involves invasive procedure, they 
are not subjects for the development of noninvasive tests. 
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1.4.1 Amniotic fluid 
The presence of cell-free fetal DNA in amniotic fluid (AF) was first demonstrated by 
Bianchi et al. (2001). It was found that the concentration of fetal DNA in AF was 
approximately 100- to 200-fold more than that in maternal plasma. However, unlike 
cell-free DNA in maternal plasma whose origin is from the placenta, Lun et al (2007) 
showed the non-placental origin of cell-free fetal DNA in AF using an epigenetic 
approach. 
The large quantity of amniotic cell-free fetal DNA has prompted researcher to 
explore its diagnostic potentials. For example, Larrabee et al. (2004) demonstrated 
the use of amniotic cell-free fetal DNA in the diagnosis of fetal gender and 
aneuploidy (Down and Turner syndrome) using comparative genomic hybridization 
(CGH) analysis. In addition, Lap aire et al (2007) showed that the unique 
fragmentation signatures of amniotic cell-free fetal DNA are potentially indicative of 
different fetal aneuploidies (Lapaire et al 2007). 
The presence of cell-free fetal mRNA in AF was first demonstrated by Larrabee et al 
(2005). However, in AF, the level of cell-free fetal mRNA appears to be much lower 
than that of cell-free fetal DNA (Larrabee et al 2005). Moreover, these mRNAs are 
not expressed in the placenta (Larrabee et al. 2005), and thus may not be useful for 
diagnosing conditions involving placental pathology, e.g. pre-eclampsia and 
intra-uterine growth restriction. Although such cell-free nucleic acids may have value 
for prenatal diagnosis, it should be bear in mind that the collection of AF for such 
testes is an invasive procedure and impose a definite risk of miscarriage. 
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1.4.2 Cerebrospinal fluid (CSF) 
In pregnant women receiving spinal anesthesia for cervical cerclage, cesarean 
delivery or postpartum tubal ligation, Angert et al. (2004) were the first to 
demonstrate the presence of cell-free fetal DNA in CSF. In particular, the detection of 
fetal DNA in CSF postpartum demonstrated a different clearance profile from that in 
the plasma/serum (Lo et al. 1999e). Although the detection showed a limited 
sensitivity, with only four out of 26 cases with detectable fetal DNA, this study 
illustrated the passage of circulating cell-free fetal DNA across the blood brain 
barrier. 
1.4.3 Peritoneal fluid 
In a case study, Cioni et al. (2003) reported the presence of male cell-free fetal DNA 
in the peritoneal fluid of a pregnant woman with a male fetus. Further studies are 
required to confirm the findings and to precisely define the origin of these sequences. 
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CHAPTER 2: MICRORNA IN HUMANS 
2.1 Introduction 
MicroRNAs (miRNAs) are a family of small (21-25 nucleotides), non-coding RNAs 
that negatively regulate gene expression at the post-transcriptional level (Ambros 
2003，Lai 2003, Battel 2004). In the early 1990s, the first miRNA, lin-4, was 
discovered in C. elegans as small temporal RNA (stRNA) which regulates 
developmental transition (Lee et al 1993). Studies on this novel class of RNAs 
remained quiescent until 2000, when let-7, another stRNA in C.elegans, was 
discovered (Lagos-Quintana et al 2001, Lau et al 2001, Lee and Ambros 2001). 
Since then, the term “miRNA，’ was coined as recognition to the importance of such 
small RNAs with important regulatory functions. Hundreds of miRNAs have been 
discovered across different species, with diverse expression patterns and regulation 
of various functions, such as developmental and physiological processes. 
In the human genome, it has been estimated that there are over 800 miRNAs 
(Bentwich et al. 2005). They regulate expression of about 30% of the protein coding 
genes (Lewis et al 2005, Xie et al 2005). Over 450 miRNAs have been documented 
to-date (Griffiths-Jones 2004). Intensive cloning and computational approaches 
continue to reveal additional miRNAs. Exponential growth in the field has added a 
new dimension to our understanding of the complex gene regulatory networks in 
different biological processes. 
2.2 Biogenesis 
2.2.1 Transcription of microRNA genes 
MiRNAs are encoded as genes. Most of them are expressed as independent 
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transcription units (Lagos-Quintana et al. 2001, Lau et al. 2001，Lee and Ambros 
2001). In addition, some miRNAs are located in the introns of pre-mRNAs (Aravin 
et al. 2003, Lagos-Quintana et al 2003, Lai et al. 2003). This arrangement allows the 
coordinated expression of a miRNA and a protein (Aravin et al 2003). Of particular 
interest, some other miRNAs are clustered in the genome. It implys transcription of 
miRNAs as a multi-cistronic primary transcript (Lagos-Quintana et al 2001，Lau et 
al. 2001) sharing functional relationships. 
The expression of miRNAs shows distinct profiles in different tissue/cell types and at 
different time. It is speculated that this property allows ample opportunity for 
‘‘micromanaging” the output of the transcriptome (Bartel 2004). In addition, 
expression of miRNAs can result in an abundant number in cells (Lim et al 2003), 
reaching as many as 50,000 mature molecules per cell. Such findings implied either 
the more active transcription of miRNAs or an unexpected stability associated with 
miRNAs. 
The genes of miRNAs are first transcribed into a miRNA precursor, 
primary-microRNA (pri-miRNA), before subsequent processing into biologically 
active and mature forms. Intron-residing miRNA genes share the same promoter 
elements and pre-mRNA transcripts with their host protein-coding genes 
(Lagos-Quintana et al 2003). On the other hand, independent miRNA genes and 
clustered miRNA genes are transcribed from their own promoters into their own 
pri-miRNAs (Lagos-Quintana et al 2003). In all cases, transcription of miRNAs is 
processed by RNA polymerases pol II (Bartel 2004). In addition, Chen et al (2004) 
showed that there is no obligate link between the identity of the polymerase involved 
and the downstream miRNA processing and function. 
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2.2.2 Processing and maturation of microRNA precursors 
Pri-miRNAs are very long nascent miRNA transcripts with over 1,000 nucleotides. 
Subsequent processing is needed before they can turn into biologically active mature 
miRNAs, which are �21-25 nucleotides long. 
Drosha cleavage ofpri-miRNA 
Inside the nucleus, the nascent pri-miRNA, which is over 1,000 nucleotides long, 
folds within itself to form a number of stem-loop structures. It is cleaved by Drosha 
RNase III endonucleases at sites near the base of the primary stem loop to release a 
�60-70 nucleotides long stem-loop miRNA precursor, the pre-miRNA (Lee et al. 
2002b, Zeng and Cullen 2003). This Drosha cleavage has specificity in defining the 
ends and the identity of the mature miRNA, probably through recognition of 
secondary structures and element flanking the primary stem loop (Lee et al. 2003). 
The resulting pre-miRNA is actively transported from the nucleus to the cytoplasm 
by Ran-GTP and the export receptor Exportin-5 (Yi et al. 2003, Lund et al. 2004). 
Dicer cleavage ofpre-miRNA 
In the cytoplasm, Dicer RNase III endonucleases recognize and cleave at a 
double-stranded stem next to the base of the stem-loop pre-miRNA (Lee et al. 2003). 
The cleavage releases an imperfect duplex of the mature miRNA, -21-25 nucleotides 
long, and a similar-sized fragment derived from the opposing arm of the pre-miRNA, 
the miRNA* (Lau et al. 2001). This miRNA:miRNA* duplex is expected to be 
short-lived, as suggested by the 100-fold less cloning frequency of the miRNA* than 
that of the miRNA strand (Lagos-Quintana et al. 2002, Aravin et al. 2003, Lim et al 
2003). 
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RNA-induced silencing complex (RISC) Assembly 
Subsequent processing of the miRNA:miRNA* processing resembles the 
posttranscriptional gene silencing pathway of RNAi and involves the 
ribonucleoprotein complex (miRNP) (Mourelatos et al. 2002)，which is a kind of 
RISC. Upon loading onto the RISC, miRNA* of the miRNA:miRNA* duplex 
detaches and degrades. The resulting RISC-miRNA complex will conduct sequence 
specific posttranscriptional silencing activities. 
2.3 Mechanisms of gene regulation 
The exact mechanism behind miRNA mediated gene regulation remains unknown. In 
humans, the two most commonly recognized mechanisms are cleavage of mRNA and 
translational repression. In general, if the miRNA has sufficient complementarity to 
the mRNA, cleavage of mRNA happens. On the contrary, if there is insufficient 
complementarity to be cleaved but does have a suitable constellation of miRNA 
complementary sites, productive translation of the mRNA is repressed (Hutvagner 
and Zamore 2002, Zeng et al 2002, Doench et al 2003, Zeng et al 2003). 
2.3.1 Cleavage of target mRNA 
If the RISC-miRNA complex binds with enough complementarity to the target 
mRNA, it induces cleavage between the nucleotides on the mRNA paired to residues 
10 and 11 of the miRNA (Kasschau et al 2003, Palatnik et al 2003). The site of 
cleavage does not change even if the miRNA is not perfectly paired to the target at 
the 5' terminus, and it can be located along the whole mRNA. After mRNA cleavage, 
the RISC-miRNA complex remains intact for cleavage of other mRNAs (Hutvagner 
and Zamore 2002, Tang et al 2003). 
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2.3.2 Translational repression of mRNA 
In general, miRNAs in metazoan cells regulate gene regulation by translational 
repression, mainly because of the less extent of complementarity between miRNAs 
and mRNAs in metazoans (Rhoades et al 2002). The complementary site of 
miRNAs resides on the 3，UTR of the target mRNAs (Reinhart et al 2000, 
Brennecke et al. 2003, Zeng and Cullen 2003). This mechanism of 
posttranscriptional regulation is featured with a drop in target protein level without a 
change in the target mRNA level (Wightman et al 1993). In particular, the combined 
action of multiple miRNAs on a single mRNA target was shown to have the most 
efficient translational repression (Lee et al. 1993, Wightman et al 1993, Reinhart et 
al 2000, Abrahante et al. 2003, Doench et al. 2003, Lin et al. 2003). However, the 
exact repression mechanism, whether it is because of captured translational initiation 
or stalled ribosome at post-initiation stages (Olsen and Ambros 1999), remains to be 
elucidated. 
2.4 Functional roles of microRNAs 
MiRNAs play important roles in various biological processes in humans and other 
vertebrates. Since miRNAs are usually highly conserved between different organisms, 
studies conducted in different model organisms provide important understanding of 
the functional roles of miRNAs in human. Other insights on miRNAs are also 
accumulating from studies in primary malignant tissue and cancer cell lines. 
2.4.1 Oncogenesis 
MiRNAs play important roles in the pathogenesis of cancer in human (Chen 2005). 
Some microRNA genes are located in regions of translocation or deletion 
characteristic to certain cancers. Subsequent loss of regulatory function results in 
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cancer. For example, the niiR-15a-miR16-l cluster located on chromosome 13ql4 is 
commonly deleted in chronic lymphocytic leukemia (CLL) (Calin et al 2002). Point 
mutation of the miR-16-1 precursor also leads to CLL (Calin et al 2005). Moreover, 
some miRNAs are regulators of commonly recognized oncogenes and 
tumor-suppressor genes. Altered expressions of these miRNAs result in oncogenic 
gene expression. For example, in some human lung cancers, reduced let-7 expression 
results in increased oncogenes, RAS, expression (Johnson et al. 2005). In addition, 
miRNAs can act as oncogenes or tumor-suppressors themselves. For example, in 
human B-cell lymphomas, the highly expressed miR-17-92 cluster can augment the 
oncogenic effect the c-Myc gene (He et al. 2005). Given the specificity of gene 
regulation by miRNAs, it was suggested that miRNA expression profiling can 
classify cancers more efficiently than mRNA expression profiling (Lu et al 2005). 
Thus, miRNAs can potentially be used to develop more efficient methods of cancer 
diagnosis and treatment. In particular, target prediction of cancer-related miRNAs 
can potentially enhance the discovery on a new class of tumor suppressors and 
oncogenes as target for diagnosis and therapy. 
2.4.2 Programmed cell death 
The association of miRNA with oncogenesis is probably a result of the role of 
miRNA in regulating programmed cell death (apoptosis). Up to date, most studies of 
the regulation of miRNA on programmed cell death in humans are related to cancer. 
For example, in glioblastoma, a highly malignant human brain tumor, miR-21 is 
strongly expressed. Chan et al. (2005) demonstrated the inhibitory effect of miR-21 
on apoptosis with measurement of the caspase-3 and caspase-7 enzymatic activity, 
and terminal deoxynucleotidy 1 -mediated dUTP nicked labeling staining. In addition, 
miR-16-1 and miR-15a were found to be negatively repressing the expression of 
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Bel2, a proapoptotic protein (Cimmino et al. 2005). Reduced expression of the two 
miRNAs inhibits apoptosis and results in CLL. 
2.4.3 Cellular differentiation and development 
Complex networks of biomolecular interaction are involved during the development 
of animals. Using different model organisms, studies showed that miRNAs are 
essential for the normal development of animals. 
During early stages of human embryonic stem (ES) cell development, a specific set 
of miRNAs are downregulated upon differentiation of human ES cells into embryoid 
bodies (Suh et al. 2004). These observations suggested that specific profiles of 
miRNAs expression are needed for the correct differentiation of the zygote into 
different cell types. The importance of miRNA was further demonstrated in the 
zebrafish and mouse with mutant Dicer, whose ES cells could not produce mature 
miRNA that failed to differentiate (Bernstein et al. 2003，Wienholds et al 2003, 
Kanellopoulou et al 2005). 
The tissue-specificity pattern of miRNA expression during embryonic developments 
suggested the importance of miRNAs in the differentiation of different cell/tissue 
types (Wienholds and Plasterk 2005). A number of studies also reported the 
developmental functions of different miRNAs. For example, miR-1 controls 
cardiomyocytes differentiation and development in mice (Zhao et al. 2005); miR-181 
directs hematopoietic lineage differentiation in B-lymphocytes of mouse bone 
marrow and the thymus (Chen et al 2004); miR-143 promotes adipocyte 
differentiation or functioning (Esau et al. 2004). In particular, Seitz et al. (2003, 2004) 
reported the association of miR-127 and miR-136 with imprinting during normal 
development in humans. 
27 
Micro RNA in human 
2.4.4 Regulation of physiological and cellular processes 
Besides being involved in oncogenesis and cellular development, several miRNAs 
are involved with various physiological and cellular processes in different organisms. 
For example, miR-375 expressed in murine pancreatic islets cells regulates 
glucose-stimulated insulin exocytosis (Poy et al. 2004). MiR-122a, differentially 
expressed in mouse testis during spermatogenesis, was reported to be involved in 
chromatin remodeling during spermatogenesis (Yu et al 2005). 
2.5 Aim of this thesis 
The presence of cell-free nucleic acids in different bodily fluids in humans has 
enabled various noninvasive diagnostic tests. This thesis aims at investigating the 
biological characteristics and diagnostic implications of another two novel classes of 
cell-free nucleic acids in human bodily fluids. 
In the second section of this thesis, I studied circulating miRNA in pregnant women. 
The existence and quantitative detection of miRNA in human plasma have not been 
reported in the literature at the time of this writing. I aimed to address the various 
challenges which might hamper the development of miRNA in plasma as diagnostic 
markers. In Chapter 4, methods for quantification of miRNA was developed and 
evaluated in detail. The feasibility of plasma miRNA detection was also addressed. In 
Chapter 5, a list of candidate pregnancy-specific miRNA markers was developed 
systematically using the quantitative methods described. Besides, various biological 
characteristics of cell-free miRNA in plasma were described. 
Cell-free DNA in urine has attracted much attention for its development into a tool 
for noninvasive diagnosis. However, there is no consensus on a method for 
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quantitative analysis of cell-free DNA from urine. Moreover, an accurate analytical 
system for quantifying the proportion of DNA that passes through the kidney barrier 
into the urine is lacking. In the third section of this thesis, in Chapter 6, I studied the 
possibility of Tr-DNA analysis in hematopoietic stem cell transplantation recipients. 
Finally, in Chapter 7, a general conclusion of the studies and the future perspectives 
of cell-free nucleic acids in human bodily fluids as diagnostic tools are presented. 
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CHAPTER 3: QUANTITATIVE ANALYSIS OF CIRCULATING 
AND URINARY NUCLEIC ACIDS 
3.1 Preparation of samples 
3.1.1 Preparation of plasma 
Peripheral blood was collected into ethylenediaminetetraacetic acid 
(EDTA)-containing blood tubes. EDTA can work as an anticoagulant by chelating the 
calcium molecules in blood since calcium is needed for coagulation to occur. Plasma 
was harvested by double-centrifugation of the blood to minimize blood cell 
contamination (Chiu et al 2001). The blood samples were first centrifuged at 1600 g 
for 10 min at 4�C (Centrifuge 5810R, Eppendorf, Germany). Plasma samples were 
carefully transferred into plain polypropylene tubes and re-centrifuged again at 
16,000 g for 10 min at 4 � C (Centrifuge 5415R, Eppendorf, Germany). The 
‘‘cell-free，’ supematants were collected into a fresh polypropylene tube. 
For DNA studies, plain plasma was stored at -20°C until DNA extraction. For RNA 
studies, 1 mL of TRIzol LS Reagent (Invitrogen, CA, USA) was mixed thoroughly 
with 800 |iL of plasma before storage at -80�C. The storage of plasma with TRIzol 
LS (Invitrogen) is critical for preservation of RNA integrity. Wong et al (2004a) 
have recently demonstrated the superior integrity of RNA in plasma that had been 
stored with TRIzol (Invitrogen) for three years, comparing with the same plasma 
samples which had been stored alone without the TRIzol LS (Invitrogen) (Wong et al 
2004a). 
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3.1.2 Preparation of blood cells 
Peripheral blood was collected into EDTA-containing tubes and subjected to 
centrifugation at 1,600 g for 10 min at 4°C (Centrifuge 581 OR, Eppendorf, Germany). 
Buffy coat is the fraction of a centrifuged blood sample that contains most of the 
white blood cells and platelets, settling between the plasma (top layer) and the red 
blood cells (bottom layer). After centrifugation, the buffy coat was carefully 
transferred into fresh polypropylene tubes and re-centrifuged again at 2,300 g for 5 
min at room temperature (Centrifuge 5415R, Eppendorf, Germany). The upper 
residual plasma was removed to obtain the lower blood cell layer. 
For DNA studies, the blood cell fraction was stored at -20°C until DNA extraction. 
For RNA studies, 900 p^ L of TRIzol LS Reagent (Invitrogen) was mixed thoroughly 
with 300 jjL of the blood cell fraction before storage at -80�C. 
3.1.3 Preparation of placental tissue 
Placental tissues were obtained from pregnant women immediately after elective 
cesarean delivery. They were stored in RNAlater™ solution (Ambion®, Austin, TX) 
according to manufacturer's instructions immediately upon collection. The samples 
were stored at -80°C until RNA extraction. 
3.1.4 Preparation of urine and urine cell pellet 
Spontaneous urine specimens were collected into sterile plain bottles. The specimen 
was mixed with 0.5 mol/L EDTA (Invitrogen, Carlsbad, CA), pH 8.0, to a final 
concentration of 10 mmol/L to inhibit possible nuclease activities (Milde et al. 1999, 
Botezatu et al 2000). To separate the cell-free and cellular portion of urine, total 
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urine was firstly centrifuged at 3000 g at 4®C for 10 min. The supematants were then 
filtered through a 0.45 ^m filter (Milex-GV; Millipore, Billerica, MA) to remove any 
remaining cells or cell debris. Filtered urine was considered cell-free and was then 
stored at —80 °C until DNA extraction. The urinary cell pellet following 
centrifugation was washed with IX phosphate buffered saline (Invitrogen, Carlsbad, 
CA) twice before storage at -20 "^ C for subsequent DNA extraction. 
3.2 Nucleic acid extraction 
3.2.1 Extraction of small RNA-containing total RNA from plasma, blood cells 
and placental tissue 
Plasma and blood cells RNA was isolated by a method modified from the procedure 
used for plasma and buffy coat RNA isolation (Ng et al. 2002，Ng et al 2003b). It 
was a combination of the use of TRIzol LS Reagent (Invitrogen) and the m/rVanaTM 
miRNA isolation kit (Ambion®, Austin, TX), Figure 3.1. Based on the single-step 
RNA isolation method developed by Chomczynski and Sacchi (1987), TRIzol LS 
Reagent (Invitrogen) is a monophasic solution of phenol and guanidine 
isothiocyanate, which is capable of denaturing proteins, including ribonucleases, thus 
preserving the integrity of ribonucleic acids. Because plasma is a protein-rich bodily 
fluid, the TRIzol LS Reagent (Invitrogen) was used for the complete denaturation of 
protein so that more RNA could be released from its binding cellular proteins. The 
procedure also prevents protein coagulates from clogging the downstream extraction 
column. The w/rVana'^^ miRNA Isolation Kit (Ambion) is a column-based RNA 
isolation technology. Unlike other RNA extraction columns which were unable to 
retain very small RNA sized below 200 nucleotides, the filter cartridge (Ambion) 
was specially designed for purification of small RNAs, inculding miRNA, which are 
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about 21-25 nucleotides long. It involves an organic extraction followed by 
immobilization of RNA on glass-fiber filters to purify small RNA-containing total 
RNA using a microspin protocol. This approach does not involve the use of cesium 
chloride gradient ultracentrifugation or alcohol precipitation, which is relatively 
time-consuming and labor-intensive, therefore providing a fast and simple alternative 
for the preparation of RNA from blood samples. Placental tissue RNA was isolated 
by a method similar to that in plasma and blood cells. However, TRIzol Reagent 
(Invitrogen) was used instead of TRIzol LS Reagent (Invitrogen) for solid tissue 
RNA extraction. 
For the isolation of total RNA from plasma, 1.6 mL of each sample was mixed with 2 
mL of TRIzol LS Reagent (Invitrogen) and 0.4 mL of chloroform. For the isolation 
of total RNA from blood cells, 0.3 mL of each sample was mixed with 0.9 mL of 
TRIzol LS Reagent (Invitrogen) and 0.24 mL of chloroform. For isolation of total 
RNA from placental tissues, 50-100 mg of placental tissue was homogenized in 1.5 
mL TRIzol Reagent (Invitrogen), and 0.3 mL chloroform was added. Cell-debris was 
removed by centrifugation at 12,000 g for 15 min at 4°C (Centrifuge 5415R; 
Eppendorf). To 1.5 mL of homogenate, 0.4 mL of chloroform was added and mixed. 
The mixtures were separated into different phases by centrifugation at 12,000g for 15 
min at 4°C (Centrifuge 5415R; Eppendorf, Germany): RNA in the aqueous phase, 
DNA in the interphase, and proteins at the organic phase. The aqueous layer was 
carefully removed and transferred into fresh polypropylene tubes. 
Total RNA in the aqueous layer was then extracted using the mzrVanaTM miRNA 
Isolation Kit (Ambion) according to the manufacturer's protocols. First, for adjusting 
the filter cartridge binding conditions, 1.25 volumes of absolute ethanol were added 
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to one volume of the aqueous layer. The mixture was applied to m/rVana'^^ filter 
cartridges (Ambion) followed by centrifugation at 10,000 g for 10 sec (Centrifuge 
5415D; Eppendorf), during which total RNA was adsorbed to the membrane. After 
all mixture was passed through the filter cartridge, 700 |LIL of miRNA Wash Solution 
1 (proprietary to the manufacturer) was loaded onto the filter cartridge to wash away 
contaminants by further spins under the same conditions. Afterwards, the filter 
cartridge was subjected to another 500 |LIL of miRNA Wash solution 2/3 (proprietary 
to the manufacturer). High-speed centrifugation at 10,000 g for 1 min (Centrifuge 
5415D; Eppendorf) was then performed for the complete removal of residual buffer 
from the membrane. Lastly, to elute RNA from the filter cartridge, 100 \xh of 
pre-heated RNase-free water (at 95^C) was added directly onto the membrane and 
incubated at room temperature for 1 min, followed by centrifugation at 10,000 g for 
1 min (Centrifuge 5415D; Eppendorf). 
At this stage, to ensure isolation of pure RNA from the samples, DNase I digestion 
was performed using the Amplification Grade DNase I (Invitrogen, Carlsbad, CA). 
After elution from the m/rVana^^ filter cartridge (Ambion), each RNA sample was 
quantified using the NanoDrop® ND-1000 UV-Vis Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). For digestion, the following four components were 
added to fresh microcentrifuge tubes on ice: 1 i^ g of RNA sample, 1 \iL of DNase I, 1 
of lOX Reaction Buffer, and RNase-free water to 10 \xh. This reaction mixture 
was incubated at room temperature for 15 min, followed by the addition of 1 jiiL of 
25 mM EDTA solution and incubation at 65�C for 10 min for to inactivate DNase I. 
The treated RNA samples were then stored at -80°C prior to analysis within 2 weeks. 
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P ^ ^ , (4) Add ethanol 
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(2) Chloroform mT 
[• (5) Filter cartridge 
^ ^ V binds total RNA 
卞 r 
L � 
\ J (6) Buffer washes 
( � 1 W (3) Transfer aqueous \J (7) pinal RNA elution 
phase to a new tube 
Figure 3.1 Procedure for RNA extraction from plasma, blood cells and placental 
tissue. (Modified from mirVana^^ miRNA Isolation instruction manual, Ambion, 
2006) 
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3.2.2 Extraction of DNA from plasma, blood cells and urine cell pellet 
DNA was extracted from plasma, blood cells and urine cell pellet using the QIAamp 
DNA Mini Kit (Qiagen, Germany) according to the 'blood and bodily fluid spin 
protocol' (Lo et al. 1998b). For plasma DNA extraction, 800 \iL of plasma was used. 
For blood cell DNA extraction, 300 \iL of buffy coat was used. For urine cell pellet 
DNA extraction, urine cell pellet was first resuspended in 200 \xL of IX phosphate 
buffered saline (Invitrogen) before DNA extraction. For each 400 [iL of fluid sample, 
40 JIL of QIAGEN Protease and 400 |liL of AL buffer were added and the mixture 
was incubated at 56�C for 10 min. After that, 400 juL of cold absolute ethanol was 
added. The mixture was transferred onto a QIAamp Spin Column and centrifuged at 
16,000 g for 1 min. The extraction column was washed twice with AWl and AW2 
buffers, at 16,000 g for 1 min and 3 min, respectively. DNA was finally eluted in 50 
|liL of deionized water, by centrifugation at 16,000 g for 1 min. The extracted DNA 
was stored at -20°C until analysis. 
3.2.2 Extraction of DNA from urine 
For extraction of DNA from the filtered cell-free urine, 15 mL of 6 mol/L guanidine 
thiocyanate (Sigma-Aldrich, Helios, Singapore) and 1 mL of resin (Wizard DNA 
Isolation Reagent Set; Promega, San Luis Obispo, CA) were mixed with 10 mL of 
the processed urine (Su et al. 2004b). The mixture was then incubated with gentle 
mixing at room temperature for two hours. The resin-DNA complex was then 
isolated and washed with wash buffer provided by the manufacturer on minicolumns 
(Wizard DNA Isolation Reagent Set; Promega). Urine DNA was then eluted in 100 
/xL deionized free water. 
37 
Quantitative analysis of circulating nucleic acids 
3.3 Quantitative measurements of nucleic acids 
3.3.1 Principle of real-time quantitative PCR 
Real-time quantitative PCR systems allow robust and accurate detection of nucleic 
acids in human bodily fluids. In this thesis, the real-time quantitative PCR (QPCR) 
(Heid et al 1996) was employed for quantitative measurement of DNA. Real-time 
quantitative reverse-transcriptase PCR (QRT-PCR) (Gibson et al 1996) was 
employed for the quantitative measurement of mRNA and microRNA. A typical 
TaqMan® based real-time quantitative PCR compose of the following major 
components: 
TaqMan® probe 
A TaqMan® probe is a single-stranded synthetic oligonucleotide with a dual-labeled 
fluorescent reporter dye at the 5' end and a quencher dye at the 3’ end. In a reaction 
mixture of QPCR or QRT-PCR, if the probe is not annealed to the target sequence, it 
would be intact. The proximity of the reporter dye to the quencher dye results in 
suppression of the reporter fluorescence because of energy transfer. If the target 
sequence is present, the probe specifically hybridises to the target sequence. The 
DNA polymerase, which possesses the 5' to 3' nuclease activity, cleaves the probe. 
The reporter and the quencher become separated, resulting in an increased 
fluorescence emission by the reporter. Accumulation of PCR products was detected 
directly by monitoring the increase in fluorescence of the reporter. The use of this 
type of fluorogenic probe allows great specificity as only the amplification of the 
intended sequence is measured, while primer-dimers and non-specific PCR products 
are not detected. 
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Sequence detector 
The implementation of real-time quantitative polymerase chain reaction techniques 
requires suitable instrumentation capable of combining amplification, detection and 
quantification. All assays described in this thesis were performed on the ABI™ Prism 
7300 Sequence Detector or the ABI™ Prism 7900 Sequence Detector (Applied 
Biosystems, Foster City, CA, USA). These machines contain an in-built thermal 
cycler, a neon lamp or laser to induce fluorescence of the dye, and a charge-coupled 
device (CCD) camera. During real-time quantitative PCR, reactions were carried out 
in closed, optical tubes of a 96-well microplate. A laser/neon light was directed to 
each reaction via optical fibers and the resulting fluorescent emission data were 
collected with the CCD camera as the PCR products were being generated. 
Software tool 
Sequence Detection System (SDS) Software vl.2.3 (Applied Biosystems, Foster City, 
CA, USA) was used for the acquisition and analysis of data. Quantification of 
nucleic acids was achieved by detecting the corresponding threshold cycle (CT). The 
Ct value is the cycle number at which the reporter signal begins to exceed a 
threshold above the baseline signal. This value is inversely proportional to the 
starting quantity of the target template. 
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3.3.2 One-step QRT-PCR assays for mRNA quantification 
3.3.2.1 Principle 
Messenger RNA was measured by one-step QRT-PCR using components provided 
by the TaqMan® EZ RT-PCR Kit (Applied Biosystems, Foster City, CA, USA). This 
is a single-tube, single enzyme quantitative system enabled with the use of the 
recombinant Thermus thermophilus {xTth) DNA polymerase, which functions both as 
a reverse transcriptase and a DNA polymerase (Myers and Gelfand 1991). RNA is 
first reverse transcribed to cDNA by sequence-specific primer. Then, in the PCR 
amplification, the 5' to 3' nucleolytic activity of the xTth DNA polymerase cleaves 
hybridized TaqMan® probe separating the reporter dye and quencher dye on the same 
probe (Holland et al. 1991). This results in an increase in fluorescence signal which 
is subsequently detected and analyzed by the sequence detector. 
To allow precise quantification of mRNA in terms of copy numbers, standard curve 
for absolute quantification was constructed by serial dilutions of high performance 
liquid chromatography (HPLC)-purified single stranded synthetic DNA 
oligonucleotides specifying the studied amplicons. The use of synthetic DNA 
oligonucleotides was previously shown to be able to reliably mimic the reverse 
transcription step and produce standard curves that are identical to those obtained 
using T7-transcribed RNA (Bustin 2000). 
3.3.2.2 Quantification of human placental lactogen (hPL) mRNA 
In this thesis, one step real time RT-PCR was used for quantification of the hPL 
mRNA. The sequence information for the primers (Integrated DNA Technology, 
Coralville, lA), and probes (Proligo，Helios, Singapore) is given in Table 3.1. For the 
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TaqMan® probe of the hPL assay, the dual-labeled fluorescent probe contained 
6-carboxyfluorescein (FAM) as the reporter dye at the 5' end and 
6-carboxytetramethylrhodamine (TAMRA) as the quencher dye at the 3，end. In 
order to avoid cross-reactivity of the assay to amplify genomic DNA, the assay was 
designed with a pair of intron-spanning primers. 
One-step quantitative RT-PCR was set up in a reaction volume of 50 jtiL using the EZ 
xTth RNA PCR Reagent Kit (Applied Biosystems, Foster City, CA, USA). Table 3.2 
summaries the preparation of the QRT-PCR reaction mixture and the thermal profile 
of the amplification. To each 50 (xL of reaction mixture, 3 fxL of extracted plasma 
RNA or 1 ng of extracted buffy coat/placental tissue RNA was added as template. In 
each analysis, calibration curve was included for absolute quantification of the target 
RNA (Chapter 3.3.2.1). The standard curve was constructed using serial dilutions of 
synthetic DNA oligonucleotides (Proligo, Singapore) on the hPL amplicon with 
Q 
concentrations ranging between 1.25 x 10 and 12.5 copies per reaction. At the same 
time, the analysis was run with at least four no template control reactions to monitor 
the level of contamination. The reaction was initiated with 2 min incubation at 50 °C 
for contamination control with UNQ followed by RT at 60 °C for 30 min. After 
deactivation of UNG at 95 °C for 5 min, the reaction was cycled for 45 times with 
denaturation at 94 °C for 20 s and 1 min of annealing/extension at 5 6 � C . 
The absolute concentration of the hPL mRNA in each sample was calculated using 
one of the following formulas: 
p^lasma — QX(VRNA/Vext) 
Cbuffy coat/placental tissue — Q / Cinput RNA 
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where Cpiasma is the hPL mRNA concentration in plasma (copies/mL of plasma); Q is 
hPL mRNA quantity determined by sequence detector (copies//xL of RNA sample); 
VRNA is the total volume of RNA solution after the RNA extraction and DNase I 
treatment; Vext is the volume of plasma used for extraction; Cbuffy coat/piacentai tissue is the 
hPL mRNA concentration in buffy coat or placental tissue (copies/ng of total RNA); 
Cinput RNA is the concentration of the input total RNA determined by sequence 
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Table 3.2 One-step QRT-PCR assay for quantification hPL mRNA. 
(A) Composition of one-step QRT-PCR reaction mixture (EZ xTth RNA PCR 
Reagent Kit; Applied Biosystems) 
^ • Volume per reaction Final Components f ^, 丄丄. (^L) concentration 
5X TaqMan EZ Buffer 10 IX 
Mn(0Ac)2 (25 mM) 6 3 mM 
dATP(lOmM) 1.5 300 jiiM 
dCTP(lOmM) 1.5 300 juM 
dGTP(lOmM) 1.5 300 |LIM 
dUTP (20 mM) 1.5 600 _ 
Forward Primer (10 |iM) 1.5 300 nM 
Reverse Primer (10 |LIM) 1.5 300 nM 
Probe (5 1 100 nM 
AmpErase UNG (1 U/|LiL)b 0.5 0.01 U/^iL 
xTth D N A Polymerase ( 2 . 5 U / ^ I L ) 2 0 . 1 U/|LIL 
RNase-free water 18.5 -
RNA sample 3 -
Total 50 -
a Dual-labeled fluorescent probe containing a reporter at the 5 ‘ end (FAM, 6-carboxyfluorescein) and a 
quencher at the 3 ' end (TAMRA, 6-carboxytetramethylrhodamine). 
b U N G = uracil-N-glycosylase 
(B) Thermal profile of one-step QRT-PCR reaction 
Step Temperature Time 
UNG treatment 50 °C 2 min 
Reverse Transcription 6 0 � C 30 min 
Deactivation of UNG 9 5 � C 5 min 
Denaturation 94 °C 20 s 
45 Cycles 
Annealing / Extension 5 6 � C 1 min 
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3.3.3 Two-step QRT-PCR assays for microRNA quantification 
3.3.3.1 Principle 
MicroRNA in RNA samples was measured by a two-step QRT-PCR assay using 
components provided by the TaqMan® MicroRNA Reverse Transcription Kit and the 
TaqMan® MicroRNA Assay (Applied Biosystems, Foster City, CA, USA). This 
two-step QRT-PCR system involves two separate procedures (Figure 3.2). 
Reverse Transcription (RT) 
In this step, a stem-loop primer hyrbridizes to the 3' end of the mature miRNA. It can 
distinguish between other highly similar mature miRNA sequences (Figure 3.2). The 
primer can also distinguish between mature miRNAs with single base difference 
(Applied Biosystems; Product bulletin on TaqMan MicroRNA Assays: Quantitate 
microRNAs with the specificity and sensitivity of TaqMan assay chemistry; accessed 
3 October 2006). Upon RT, cDNA of the microRNA is generated as an extension 
from the 3’ end of the stem-loop primer, resulting in a cDNA-DNA hybrid for 
subsequent PCR amplification. 
The Multiscribe™ reverse transcriptase used in the RT step is capable of generating 
cDNA from both microRNA and single-strand DNA. Hence, standard curve for 
absolute quantification was constructed by serial dilutions of single-stranded 
synthetic DNA oligonucleotides specifying the studied miRNAs. According to the 
results described in Chapter 4.3.1，the use of synthetic DNA oligonucleotides is able 
to reliably mimic the RT step and produce standard curves that are identical to 
synthesized RNA oligonucleotides. Since synthetic DNA oligonucleotides are less 
expensive and the commercial turn around time for their synthesis is relatively short, 
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they were used as the standard curves for my experiments. 
PCR Amylification 
The quantity of cDNA-DNA hybrid generated is directly proportional to the initial 
quantity of miRNA present in the RNA sample. Hence, the assay quantifies the 
miRNA using primers and probe amplifying the cDNA-DNA hybrid from the RT 
step (Figure 3.2). The forward primer hybridizes specifically to the cDNA portion of 
the microRNA in the hybrid; the reverse primer hybridizes specifically to the 
unfolded stem-loop sequence of the stem-loop primer in the hybrid; the probe falls 
on the junction within the hybrid. Such design further enhances the specificity of the 
assay to miRNA detection. It is also capable of generating a dynamic range of 
detection of up to seven logs. 
3.3.3.2 Advantages 
The two-step QRT-PCR system for microRNA quantification involves the use of a 
stem-loop primer and a set of specific primers and probes which has several 
important features for the detection of microRNA. 
Detection o f the very short microRNA 
QRT-PCR or QPCR requires a template of at least 60 nucleotides for primers and 
probe hybridization and efficient PCR amplification. However, mature miRNAs are 
very short, of about 21-25 bases long. They, alone，cannot provide enough target 
sequence length for primers and probe hybridization. The use of a hairpin primer for 
the generation of a cDNA-DNA hybrid provides a target template long enough for 
the subsequent PCR amplification, which is otherwise impossible. 
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Increased specificity 
The use of hairpin primer for the QRT-PCR has increased the specificity of the assay 
in several aspects. First, the hairpin primer recognizes and hybridizes to RNA with 
the exact 3，end sequence. Even a single base extension at the 3，end will result in a 
delayed threshold cycle in the detection. This allows the primer to distinguish the 
mature miRNA target from its miRNA precursors or any genomic DNA contaminants 
in the RNA samples. Second, the primers and probes used in the PCR amplifications 
are very specific to the cDNA-DNA hybrid. This has greatly enhanced the specificity 
of the assay to the target microRNA and allows the assay to differentiate between 
highly similar microRNA sequences with even a single nucleotide difference. 
3.3.3.3 TaqMan® MicroRNA Assays 
TaqMan® MicroRNA Assays (Applied Biosystems) were used for quantification of 
mature microRNA sequences. The assays were designed by and purchased from 
Applied Biosystems for different microRNA targets. The assay IDs and sequences of 
the target microRNAs used in this thesis are summarized in APPENDIX I. For the 
TaqMan® probes of all the assays, the dual-labeled fluorescent probe contained 
6-carboxyfluorescein (FAM) as the reporter dye at the 5' end and minor-groove 
binding (MGB) non-fluorogenic quencher (NFQ) at the 3’ end. 
The first step, reverse transcription (RT), was set in a reaction volume of 7.5 /xL 
using the TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems). 
Table 3.3 A and C summarize the preparation of the RT reaction mixture and the 
thermal profile, respectively. To each 7.5 /xL of the reaction mixture, 2.5 fiL of 
extracted plasma RNA or 2.5 ng of extracted buffy coat/placental tissue RNA was 
added as template. In each analysis, a calibration curve was included for absolute 
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quantification of the target RNA. The standard curve was constructed using serial 
dilution of synthetic DNA oligonucleotides (Proligo) on the target microRNA with 
concentrations ranging between 6.25 x 10^ and 62.5 copies per RT reaction. At the 
same time, the analysis was run with at least four no template control reactions to 
monitor the level of contamination in reagents used in the RT reaction. The reaction 
was initiated with a 5-min incubation at 4 for initial hybridization between 
primers and target sequences. After hybridization at 16 for 30 min, RT was 
initiated at 42 for another 30 min. Deactivation of the reverse transcriptase was 
performed at 85 °C for 5 min. 
The second step, PGR amplification, was set up in a reaction volume of 20 fiL using 
TaqMan 2X Universal PGR Master Mix, No AmpErase UNG (Applied Biosystems, 
Foster City, CA). Table 3.3 B and D summarize the preparation of the PCR 
amplification reaction mixture and the thermal profile, respectively. To each 20 fxL of 
reaction mixture, 1.33 /jlL of RT product from all the reactions was added as template. 
At the same time, the analysis was run with another four no template control 
reactions to monitor the level of contamination in the reagents used in the PCR 
reaction. 
The reaction was initiated with 10 min incubation at 95 °C for AmpliTaq Gold® 
enzyme activation and initial DNA denaturation. Then, the reaction was cycled for 40 
times with denaturation at 95 °C for 15 sec and 1 min of annealing/extension at 60 
The absolute concentration of the target sequences in each sample was calculated 
using one of the following formulas: 
Cpiasma = Q X (VRNA 丨 V e x t ) 
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Cbuf fy coat/placental tissue — Q / Cjnput RNA 
where Cpiasma is the target sequence concentration in plasma (copies/mL of plasma); 
Q is target sequence quantity determined by sequence detector (copies//xL of RNA 
sample); VRNA is the total volume of RNA solution after the RNA extraction and 
DNase I treatment; Vext is the volume of plasma used for extraction; Cbuffy coat/piacentai 
tissue is the target sequence concentration in buffy coat or placental tissue (copies/ng 
of total RNA); Cinput RNA is the concentration of the input total RNA determined by 
the sequence detector (copies/ng of RNA sample). 
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Forward TaqMan Probe Reverse 
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Figure 3.2 Two-step QRT-PCR assays for miRNA quantification. 
In the RT step, a stem-loop primer hyrbridizes specifically to the 3’ end of the mature 
miRNA. Upon reverse transcription, cDNA of the miRNA is generated as an 
extension from the 3’ end of the stem-loop primer, resulting in a cDNA-DNA hybrid 
for subsequent PCR amplification. The forward primer hybridizes specifically to the 
cDNA of the miRNA in the hybrid; the reverse primer hybridizes specifically to the 
unfolded stem-loop sequence of the stem-loop primer in the hybrid; the probe falls 
on the junction within the hybrid. QPCR was then performed for real-time detection. 
(Modified from TaqMan® MicroRNA Assays instruction manual. Applied Biosystems, 
2005) 
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Table 3.3 Two-step QRT-PCR assay for microRNA quantification. 
(A) Composition of reverse transcription (RT) reaction mixture 
^ . Volume for one Final Component ， T � ‘ ‘• reaction QiL) concentration 
lOX RT Buffer' 0.75 IX 
dNTPs (with dTTP; 100 mM)' 0.08 13.33 mM 
5X Stem-loop RT Primer'' 1.5 IX 
RNase Inhibitor (20 U//xL)' 0.09 2.67 U/ptL 
MultiScribe™ Reverse 
0.5 6.67 U//XL 
Transcriptase (50 
Nuclease-free water 2.08 -
RNA sample 2.5 -
Total 7.5 -
a Components provided by TaqMan® MicroRNA Reverse Transcription Kit, Applied Biosystems 
b Components provided by TaqMan® MicroRNA Assay, Applied Biosystems 
(B) Composition of PCR reaction mixture 
^ • Volume for one reaction Final Component , T � . . . ^ (弘 L) concentration 
TaqMan 2X Universal PCR 
Master Mix (No AmpErase 10 IX 
UNG)b’c 
TaqMan MicroRNA Assay 
Mix (lOX)d 
Nuclease-free water 7.67 -
RT Product 1.33 -
Total 20 -
a Dual-labeled fluorescent probe containing a reporter at the 5 ‘ end (FAM, 6-carboxyfluorescein) and a 
quencher at the 3 ' end (MGB NFQ, minor-groove binding non-fluorogenic quencher), 
b UNG = uracil-N-glycosylase 
e Applied Biosystems 
d Components provided by TaqMan® MicroRNA Assay, Applied Biosystems 
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(C) Thermal profile of reverse transcription (RT) 
Step Temperature Time 
Initial incubation 4 °C 5 min 
Annealing of stem-loop RT primers 16 °C 30 min 
Reverse transcription 42 °C 30 min 
Deactivation of MultiScribe™ Reverse 
85。C 5 min 
Transcriptase 
Final incubation 4。C ⑴ 
(D) Thermal profile of PCR amplification 
Step Temperature Time 
Activation of AmpliTaq Gold® 95。C 10 min 
Denaturation 95。C 15 s 
40 Cycles 。 • 
Annealing / Extension 60。C 1 min 
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3.3.4 QPCR assays for DNA quantification 
3.3.4.1 Principle 
DNA in samples was measured by QPCR using components provided by the 
TaqMan® PCR Core Reagent Kit (Applied Biosystems, Foster City, CA). The 
principle behind the quantification is similar to that of QRT-PCR, except, in QPCR, 
the AmpliTaq Gold® DNA polymerase is used and there is no reverse transcription 
step is involved. Moreover, standard curve for absolute quantification was 
constructed by serial dilutions of human male genomic DNA extracted from blood 
cells. 
3.3.4.2 Quantification of the leptin gene and the sex-determining region on Y 
chromosome gene 
QPCR assays were used for the quantification of the leptin {LEP) gene and the 
sex-determining region on Y chromosome {SRY) gene in different bodily fluids. For 
each of the LEP and SRY genes, three assays of different amplicon sizes were used. 
The sequence information for the primers (Integrated DNA Technology) and probes 
(Applied Biosystems) is given in Table 3.1. For the TaqMan® probes of all assays, 
the dual-labeled fluorescent probe contained 6-carboxyfluorescein (FAM) as the 
reporter dye at the 5' end and the minor-groove binding (MGB) non-fluorogenic 
quencher (NFQ) at the 3' end. 
QPCR was set up in a reaction volume of 50 /xL using the TaqMan® PCR Core 
Reagent Kit (Applied Biosystems). Table 3.4 summaries the preparation of the 
QPCR reaction mix and the thermal profile of the amplification. To each 50 /xL of 
reaction mixture, 5 fiL of extracted urine/plasma DNA was added as a template. In 
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each analysis, a calibration curve was included for absolute quantification of the 
target DNA (Chapter 3.3.2.1). The standard curve was constructed using serial 
dilutions of male blood cells genomic DNA with concentrations ranging between 
0.78 and 10,000 genome equivalents per five microliters. At the same time, the 
analysis was run with at least four no template control reactions to monitor the level 
of contamination. The reaction was initiated with 2 min incubation at 50 °C for 
contamination control with UNG. After deactivation of UNG at 95 °C for 10 min, the 
reaction was cycled for 50 times with denaturation at 95 °C for 30 s and 1 min of 
annealing/extension at 60 
The absolute concentration of the DNA in each sample was calculated using the 
following formula: 
Cplasma/urine = Q X (VDNA 丨 V g x t ) 
where Cpiasma/urine IS the DNA concentration in plasma/urine (copies/mL of 
plasma/urine); Q is DNA quantity determined by the sequence detector (copies/"L of 
DNA sample); VDNA is the total volume of DNA solution after the DNA extraction; 
Vext is the volume of plasma used for extraction. 
54 
Quantitative analysis of circulating nucleic acids 
Table 3.4 QPCR assay for DNA quantification of L^Pand 5i?FDNA. 
(A) Composition of QPCR reaction mixture (TaqMan® PGR Core Reagent Kit, 
Applied Biosystems) 
^ ‘ Volume for one , ‘ Component , 了� Final concentration reaction QiL) 
1 OX TaqMan Buffer A 5 IX 
MgCl2 (25 mM) 8 4 mM 
dATP(lOmM) 1 200/xM 
dCTP(lOmM) 1 200/xM 
dGTP(lOmM) 1 200 ^ uM 
dUTP (20 mM) 1 400 /xM 
Forward Primer (10 iiiM) 5 1 fiM 
Forward Primer (10 |iM) 5 1 fiM 
Probe (10 2.5 500 nM 
AmpliTaq Gold® (5 U/jaL) 2 0.025 U/ /xL 
AmpErase UNG (1 U/juhf 0.5 0.01 U/ fiL 
Dimethyl sulfoxide ，.c <；。”了 / ,,T 
(DMSO) ^ 
Deionized water 10.5 -
DNA sample 5 -
Total 50 -
a Dual-labeled fluorescent probe containing a reporter at the 5 ‘ end (FAM, 6-carboxyfluorescein) and a 
quencher at the 3 ' end (MGB NFQ, minor-groove binding non-fluorogenic quencher), 
b UNG = uracil-N-glycosylase 
CDMSO is added in all LEP assays; DMSO is replaced with deionized water in all 7 assays 
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(B) Thermal profile 
Step Temperature Time 
UNG treatment 50。C 2 min 
Deactivation of UNG and 
95。C 10 min 
Activation of AmpliTaq Gold 
Denaturation 95。C 30 s 
50 Cycles 。 
Annealing / Extension 58。C 1 min 
Final incubation 72。C 1 min 
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3.4 Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) 
3.4.1 Principle 
The MassARRAY® system (Sequenom, San Diego, CA) is an accurate and 
high-throughput technology for DNA/RNA genotyping. It is capable of resolving 
single nucleotide polymorphisms (SNPs) of DNA/RNA samples quantitatively, by 
utilizing the MALDI-TOF MS to differentiate mass difference of products generated 
from the homogeneous MassEXTEND™ (hME) assay (Sequenom, San Diego, CA). 
The hME assay consists of an initial PCR and a primer extension reaction. In the 
initial PCR, a single pair of primers flanking the region with the SNPs is used. Upon 
amplification, the PCR products of different genotypes of the SNP are produced in 
proportion to the genotypic ratio in the original nucleic acid sample. In the primer 
extension reaction, an oligonucleotide primer (extension primer) anneals to a position 
right beside the SNP of interest. Thermal cycling was then performed using a 
reaction mixture with a DNA polymerase along with a mixture of terminator 
nucleotides, a combination of different deoxyribonucleotides (dNTP) and 
dideoxynucleotides (ddNTP), which allows extension of the hME primer through the 
polymorphic site and generates allele-specific extension products with different 
unique molecular masses. MALDI-TOF MS is then used to analyze the resultant 
masses of the extension products and to report genotype of the nucleic acid samples 
(Tang et al. 1995). 
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3.4.2 Zinc finger protein gene assay for determining the fractional concentration 
of male DNA 
Zinc finger protein gene assay was used to determine the fractional concentration of 
male DNA in a mixture of male and female DNA. The fractional concentration was 
expressed as a percentage of male DNA in a mixture. In principle, the assay uses the 
MassARRAY® system (Sequenom) to determine the genotypic ratio of a single base 
difference, which is stably inherited outside the pseudoautosomal region in the X-
and Y-chromosome, in a mixture of male and female DNA. The base is inherited as 
the nucleotide T on the X-linked zinc finger protein gene {ZFX)\ it is inherited as the 
nucleotide C on the Y-linked zinc finger protein gene (ZFY). Making use of such 
allelic ratio, the proportion of male to female DNA in the DNA mixture can be 
determined. The PCR primers and the extension primer were generated by the 
MassARRAY assay design software, SpectroDESIGNER (Sequenom). The PCR and 
extension primers employed and the thermal profile of the assay are summarized in 
Table 3.5. 
The initial PCR was set up in a reaction volume of 25 /xL using the PCR components 
provided with AmpliTaq Gold® DNA Polymerase (Applied Biosystems, Foster City, 
CA). Table 3.6 A and D summarize the preparation of the PCR reaction mixture and 
the thermal profile of the amplification, respectively. A 10-mer tag with the sequence 
of 5'-ACGTTGGATG-3' was added to the 5' end of the forward and reverse PCR 
primers so that the masses of the primers would fall out of the detection range of the 
mass spectrometer. To each 25 fiL of reaction mixture, 5 fiL of extracted 
urine/plasma DNA or 50 ng of extracted buffy coat/urine cell-pellet DNA was added 
as template. At the same time, the analysis was run with at least four no template 
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control reactions to monitor the level of contamination. The reaction was initiated at 
95°C for 15 min, followed by denaturation at 95°C for 20 s，annealing at 56。C for 30 
s, extension at 72°C for 1 min for 45 cycles, and a final incubation at 72°C for 3 min. 
Shrimp alkaline phosphatase (SAP) treatment was then set up to remove 
unincorporated dNTPs in the PCR product. Table 3.6 B and D summarize the 
preparation of the SAP reaction mixture and the thermal profile, respectively. The 
reaction was initiated incubated at 37°C for 40 min to activate SAP activities, 
followed by 85°C for 5 min for SAP deactivation. 
The hME reaction was then set up for primer extension. Table 3.6 C and F 
summarize the preparation of the hME reaction mixture and the thermal profile, 
respectively. The reaction was initiated at 94°C for 2 min, followed by 94°C for 5 s, 
52°C for 5 s，and 72°C for 5 s for 75 cycles. Then, 24 \xh of water and 12 mg of the 
SpectroCLEAN Resin (Sequenom) were added to the extension products for a final 
clean up. The mixtures were mixed on a rotator for 20 min, followed by a 
centrifugation step at 361 g for 5 min. 15 to 25 nL of the final products were 
dispensed onto a SpectroCHIP (Sequenom) by a MassARRAY Nanodispenser S 
(Sequenom). Data acquisition from the SpectroCHIP was done in the MassARRAY 
Analyzer Compact Mass Spectrometer (Sequenom). Mass data were imported into 
the MassARRAY Typer (Sequenom) software for analysis. 
For the ZFX with an allelotype T, the primer extension product would have a 
sequence read as 5'- TCATCTGGGACTGTGCAA -3’ with a molecular mass of 
5498.6 Dalton (Da) For the ZFY with an allelotype C, the sequence of the primer 
extension product would be 5'- TCATCTGGGACTGTGCAGT -3, with a molecular 
mass of 5818.8 Da. This mass difference would be illustrated as two distinct peaks 
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which were resolvable by the mass spectrometer. The peak ratio of the two 
allelotypes could be used to estimate the ratio of the copy of ZFX to ZFY, which in 
turn could be used to estimate the ratio of X- to Y-chromosome. Because each male 
has one of both the X- and Y-chromosome while each female has two 
X-chromosomes, the percentage of male DNA in a mixture of male and female DNA 
was calculated using the following formulas: 
Male DNA % = (2 x Hy) / (Hx + Hy) x 100% 
where Hx is the peak height of the ZFX reported by MALDI-TOF MS and Hy is the 
peak height of the ZF7 reported by MALDI-TOF MS. 
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Table 3.5 Primer and product sequences for the zinc finger protein gene assay. 
Prim er Sequen ces (5'to 3 ’) Mass (Da) 
Forward PCR primer ACGTTGGATGGCTAAAACATCATCTGGGAC" NR^ 
Reverse PCR primer ACGTTGGATGTCATTCCTGAGCAAGTGCTG" NR^ 
Extension primer TCATCTGGGACTGTGCA 5201.4 
Extension product 1 TCATCTGGGACTGTGCAA 5498.6 
Extension product 2 TCATCTGGGACTGTGCAGT 5818.8 
^Bold font indicates the 10-mer tags added to the 5' end of the primers in such a way that the masses 
of the primers would fall out of the analytical range of the mass spectrometer. 
= not relevant. 
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Table 3.6 Zinc finger protein gene assay for quantification of male DNA 
percentage in a mixture of male and female DNA. 
(A) Composition of initial PCR reaction mixture (AmpliTaq Gold® DNA Polymerase, 
Applied Biosystems) 
^ • Volume for one reaction , . 
Component , i � Final concentration 
1 (mL) 
lOX PCR buffer I I 2.5 IX 
MgCh (25 mM) 4 4 mM 
dATP (10 mM) 0.625 250 |LIM 
dCTP (10 mM) 0.625 250 |aM 
dGTP (10 mM) 0.625 250 |LIM 
dUTP (20 mM) 0.625 500 ^M 
Forward Primer (10 |LIM) 0.5 200 nM 
Forward Primer (10 |LIM) 0.5 200 nM 
AmpliTaq Gold® DNA 0 25 
Polymerase(5 U/|aL) ‘ • ^ 
Deionized water 9.75 -
DNA sample 5 -
Total 25 -
(B) Composition of shrimp alkaline phosphatase (SAP) treatment mixture 
(Sequenom) 
Component Volume for one reaction (jiL) 
TM 
MassARRAY hME buffer 0.34 
SAP 0.6 
Deionized water 3.04 
PCR product 25 
Total 29 
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(C) Composition of homogenous MassEXTEND™ reaction mixture (Seque 
^ • Volume for one , • 
Component . , ^ � Final concentr 
reaction (juL) 
ddATP (8.96 mM) 0.1 64 ^M 
ddTTP (8.96 mM) 0.1 64 _ 
ddCTP (8.96 mM) O.I 64 juM 
dGTP (8.96 mM) 0.1 64 juM 
Extension Primer (10 |iM) 2.16 1542.86 nM 
Thermosequenase (32.94 U//iL) 0.036 0,08 U/fiL 
Deionized water 1.404 -
SAP-treated PGR product 10 -
Total 14 -
(D) Thermal profile of initial PCR 
Step Temperature Time 
Activation o f AmpliTaq Gold® 95。C 10 min 
Denaturation 95。C 30 s 
45 Cycles Annealing 5 5 � C 30 s 
Extension 72。C 30 s 
Final incubation 72。C 30 s 
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(E) Thermal profile of shrimp alkaline phosphatase (SAP) treatment 
Step Temperature Time 
Active SAP activity 37。C 40 min 
Deactivation of SAP 85 °C 5 min 
(F) Thermal profile of homogenous MassEXTEND™ reaction 
Step Temperature Time 
Activation of AmpliTaq Gold® 94。C 2 min 
Denaturation 94。C 5 s 
75 Cycles Annealing 52。C 5 s 
Extension 72。C 5 s 
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3.5 Statistical analyses 
Statistical analyses were performed with SigmaStat 3.0 software (SPSS). 
65 
SECTION III: CIRCULATING PLACENTAL 
MICRORNAS IN MATERNAL PLASMA AS 
MARKERS FOR PRENATAL DIAGNOSIS 
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CHAPTER 4: THE EXISTENCE AND QUANTITATIVE 
DETECTION OF CELL-FREE MICRORNAS IN PLASMA 
4.1 Introduction 
The discovery of fetal nucleic acids in the plasma of pregnant women (Lo et al 1997, 
Ng et al 2003b, Lo and Chiu 2007) has led to the development of a number of 
noninvasive prenatal diagnostic tests. Circulating fetal DNA in maternal plasma has 
been used for prenatal investigations of fetal rhesus D status (Faas et al, 1998, Lo et 
al 1998a), sex-linked diseases (Chiu et al. 2002b, Costa et al 2002a) and 
p-thalassemia (Chiu et al 2002b). However, these applications rely on the 
Y-chromosome sequences or the paternally-inherited polymorphisms or mutations 
for the detection of fetal DNA in maternal plasma, and thus would not be applicable 
to all pregnancies. Using the epigenetic difference between DNA in the placenta and 
the maternal blood cells, our group has developed a universal fetal DNA marker 
(Chim et al 2005), which is gender- and polymorphism-independent. Furthermore, 
our group has also discovered that placental mRNA transcripts are released into 
maternal plasma and developed them as another class of gender- and 
polymorphism-independent fetal markers. Quantitative aberrations of these 
fetal-derived placental mRNA transcripts in maternal plasma have been shown in 
conditions such as preeclampsia (Ng et al. 2003a) and fetal aneuploidies (Ng et al. 
2004). The feasibility of detecting fetal chromosomal aneuplodies noninvasively, 
using a fetal-derived PLAC4 mRNA transcript in maternal plasma, has been 
demonstrated (Lo et al. 2007). These findings have heralded a new generation of 
molecular markers for noninvasive prenatal diagnosis. 
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Recent studies on microRNAs (miRNAs) offer possibilities for developing a new 
class of molecular markers. MiRNAs are short (21-25 nucleotides), single-stranded 
and non-protein coding RNAs (Lagos-Quintana et al 2001, Lau et al 2001, Lee and 
Ambros 2001). They possess important roles in regulating gene expression through 
binding to the 3’ untranslated region of the target mRNAs (Lai 2002). These 
regulations are involved in functions such as development (Krichevsky et al. 2003), 
differentiation (Esau et al 2004), apoptosis (Baehrecke 2003) and oncogenesis 
(Michael et al. 2003, Calin et al. 2005). Although ribonuclease activity has been 
observed in plasma (Reddi and Holland 1976)，previous data have shown that plasma 
mRNAs are surprisingly stable (Ng et al. 2002), possibly through association with 
subcellular particles. Here, I hypothesised that microRNAs should also exist in 
plasma because, like mRNA, miRNAs are also present at high copy numbers (Lim et 
al 2003) and exist naturally in the cytoplasm (Yi et al 2003, Lund et al 2004). Thus, 
they may be released into plasma readily upon apoptosis. However, no data have 
been reported on whether miRNAs in human plasma might be stable enough for 
detection at the time of this writing. 
This part of the thesis aims to address the unresolved area outlined above. Here, I 
hypothesized that cell-free miRNAs exist stably in human plasma and can be 
robustly extracted for the subsequent quantification. I tested this hypothesis by first 
evaluating the use of a newly devised plasma RNA extraction protocol (Chapter 3.2.1) 
and the use of the TaqMan® MicroRNA Assay as a two-step real time QRT-PCR 
(Chapter 3.3.3) for the absolute quantification of the mature miR-16. MiR-16 is a 
miRNA highly expressed in many human tissues (Barad et al 2004). In particular, 
numerous reports have shown its presence in lymphocytes (Calin et al 2002, Calin et 
al. 2005). Therefore, it is highly probably to be present in plasma. The detection of 
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miRNA in plasma would open up new opportunities in the development of a novel 
class of circulating nucleic acid for noninvasive diagnosis of different diseases and 
conditions. 
4.2 Materials and methods 
4.2.1 Sample collection 
Peripheral blood samples were collected from pregnant women, with singleton 
uncomplicated pregnancies, just before elective cesarean delivery. Paired term 
placental tissues were also collected just after delivery. They were all in the third 
trimester of pregnancy. In addition, peripheral blood samples were collected from 
healthy volunteers with informed consent. Al l the samples were prepared using the 
protocol described in Chapter 3.1. Al l pregnant women were recruited with informed 
consent for the Department of Obstetrics and Gynaecology, Prince of Wales Hospital, 
Shatin, Hong Kong. The study was approved by the Joint Chinese University of 
Hong Kong 一 New Territories East Cluster Clinical Research Ethics Committee. 
4.2.2 Experimental design 
Validations of the two-step QRT-PCR system for miRNA quantification 
Experiment 1 
To evaluate the quantitative linearity of the assay and to address the sensitivity of the 
assay, I constructed a standard curve using a serial dilution of synthetic RNA 
oligonucleotides (Proligo) of miR-16. In a standard curve, the regression correlation 
coefficient {R^) demonstrates the degree of correlation between the RNA 
concentration and the threshold cycle (CT) generated from amplification of the target 
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sequence. It is expected that, i f the two-step QRT-PCR system is to be used for 
absolute quantification, it should have a high R within the range of detection. To 
investigate these parameters of the assay, a standard curve was constructed using a 
serial dilution of synthetic RNA oligonucleotides (Proligo) of the target sequences 
from 6.25 x 10^ to 62.5 copes per reverse transcription (RT) reaction as described in 
Chapter 3.3.3.3. The R^ and detection limits were used as the reference of analysis. 
Experiment 2 
To evaluate the precision of the miRNA quantification assay, I replicated the 
detection of 500 pg per RT reaction of a placental RNA preparation extracted and 
certified to contain miRNAs by a company (Ambion®, Austin, TX) for 20 times as 
described in Chapter 3.3.3.3. CT values and intra-assay coefficient of variation (CV%) 
of CT values were used as the reference of analysis. It was expected that i f the assay 
was highly reproducible, the assay would give very similar CT values and a very low 
analytical intra-assay CV%. 
Experiment 3 
Experiment 3 was performed to give reference for the choice of oligonucleotides as 
calibrator. The TaqMan® MicroRNA Assay (Applied Biosystems) involves the use of 
MultiScribeTM reverse transcriptase which is a recombinant Moloney Murine 
Leukemia virus (rMoMuLV) reverse transcriptase that can reverse transcribe both 
DNA and RNA oligonucleotides. This experiment was performed to investigate i f 
both DNA and RNA oligonucleotides were suitable to be used as calibrator to 
produce similar PCR efficiencies. The use of DNA, instead of RNA, oligonucleotides 
as calibrator would greatly reduce the cost of the experiments, especially in the 
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subsequent larger-scale experiments as described in Chapter 5. To evaluate the PCR 
efficiency of the assay on DNA and RNA oligonucleotides, I constructed a standard 
curve using a serial dilutions of synthetic DNA and RNA oligonucleotides (Proligo) 
of miR-16. In a standard curve, the gradient demonstrates the efficiency of the 
RT-PCR of the target sequence. It was expected that, i f both DNA and RNA 
oligonucleotides could serve as a calibrator, they would produce similar PCR 
efficiencies. To investigate this parameter of the assay, a standard curve was 
constructed using serial dilutions of both synthetic DNA and RNA oligonucleotides 
(Proligo) of the target sequences from 6.25 x 10^  to 62.5 copes per RT reaction as 
described in Chapter 3.3.3.3. The gradients and CT of corresponding calibrators were 
used as the reference of analysis. 
Experiment 4 
To evaluate the specificity of the assay to the exact mature miRNA sequence, rather 
than the miRNA precursor sequences, I compared the detection of three DNA 
oligonucleotides coding the exact sequences of miR-16, miR-16 with one base 
extension and miR-16 with fifteen bases extension at the 3’ end (Table 4.1). It was 
expected that i f the assay was specific to the mature miR-16 sequence, no or delayed 
amplification signal of the assay would be detected for the 2 oligonucleotides with 3’ 
extensions, compared to the one coding for only the exact miR-16 sequence. To do so, 
these DNA oligonucleotides (Table 4.1), diluted to 2.5 x 10^  copies/jLtL, were 
measured with the assay as described in Chapter 3.3.3.3. The CT of the detection was 
used as the reference of analysis. 
Experiment 5 
This experiment was performed to evaluate the specificity of the assay for mature 
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miRNA sequence, rather than any fragmented genomic DNA, carried over as 
contaminants of RNA extraction, with similar sequence to the short miRNA. Total 
RNA extracted from maternal blood cells as described in Chapter 3.2.1 was divided 
into four equal aliquots. They were subjected to different combinations of DNase I 
digestion (Invitrogen, Carlsbad, CA) and RNase A digestion (Fermentas, Hanover, 
MD) as shown in Figure 4.1. They were then quantified for miR-141 using the 
two-step QRT-PCR system as described in Chapter 3.3.3.3. 
Feasibility on the detection of miRNA in plasma 
Feasibility test was performed to verify the possibility of detecting of cell-free 
miRNAs in maternal plasma. Plasma samples from 20 healthy pregnant women in 
their third trimester of pregnancy were tested for the presence of cell-free miR-16 in 
the processed plasma using the two-step QRT-PCR system as described in Chapter 
3.3.3.3. In addition, the precision of this analytical system involving both miRNA 
extraction and miRNA quantification was addressed. A plasma sample was obtained 
from a randomly chosen healthy non-pregnant woman, divided into 18 identical 
aliquots, each of 0.8 rtiL, for 18 replicated miRNA extractions, and quantified for the 
concentration of miR-16. The CV% for the CJ of the two-step QRT-PCR was 
calculated. 
4.2.3 RNA extraction and quantification 
Processing of peripheral blood samples for cell-free plasma followed the procedure 
as described in Chapter 3.1.1. Two-step QRT-PCR assays for miR-16 quantification 
followed the procedure as described in Chapter 3.3.3.3. TaqMan® MicroRNA Assay 
of miR-16 was ordered from Applied Biosystems. Serial dilutions of synthetic 
oligonucleotides were used for the absolute quantification of the miR-16. 
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f 
Both DNase I and RNase A 
Extracted J Only RNase A Two-step QRT-PCR assay 
total RNA S Only ^ ^ ^ ^ ^ , — for miR-141 quantification 
No treatment 
Figure 4.1 Experimental procedures for evaluating the specificity of the two-step 
QRT-PCR assay in detecting RNA, but not DNA. 
Extracted RNA was divided into four equal aliquots which were subsequently 
subjected to different combinations of DNase I and/or RNase A treatments. The 
concentrations of miR-141 after different treatments or no treatment were quantified 
by the two-step QRT-PCR assay. 
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Table 4.1 DNA oligonucleotide sequences coding for miR-16 with and without 3， 
base extensions used for studying the specificity of the two-step QRT-PCR assay. 
Primer Sequences (5’ to 3,) 
miR-16 TAGCAGCACGTAAATATTGGCG 
miR-16+1 base TAGCAGCACGTAAATATTGGCGA 
miR-16+15 bases TAGCAGCACGTAAATATTGGCGCAGCTTAACGATATT 
^Bold font indicates the base extensions at the 3 ' end 
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4.3 Results 
4.3.1 Validation of two-step QRT-PCR system for miRNA quantification 
To assess the linearity and sensitivity of the assay, serial dilutions of the synthetic 
miR-16 RNA oligonucleotide were analyzed using the two-step QRT-PCR assay. The 
standard curve demonstrated that this quantification system had a dynamic range 
between 6.25 x 10^ and 62.5 copies of miR-16 per RT reaction and had an R^ of 0.99 
(Figure 4.2). This assay could detect down to 62.5 copies of target sequence per RT 
reaction. 
To assess the precision of the two-step QRT-PCR assay, 20 replicated quantifications 
of miR-16 in 500 pg per RT reaction of an miRNA-containing placental RNA 
preparation (Ambion®, Austin, TX) were performed. The CV% for the CT values of 
these replicated QRT-PCR was 0.53% (MeaniSD, 29.52±0.16). 
To investigate i f both DNA and RNA oligonucleotides would be suitable to be used 
as calibrators, PCR efficiencies were compared between the detections of serially 
diluted synthetic DNA and RNA oligonucleotides (Proligo) of miR-16. The gradients 
were -3.55 and -3.56 for the standard curves of DNA and RNA, respectively (Figure 
4.3). The for both of them was 0.99. The CT of corresponding calibrators was 
similar between the standard curves of DNA and RNA. This assay could detect down 
to 62.5 copies of target sequence per RT reaction. 
To evaluate the specificity of the assay for the mature miRNA sequence, the CT 
values as given by the two-step QRT-PCR assay of DNA oligonucleotides coding for 
the exact miR-16 sequence without any base extension, miR16 + 1 base, and miR-16 
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+ 15 bases at the 3，end, at the same concentrations were compared. At the same 
detection threshold, the CT values were 22.2, 24.0, and 36.1 for the oligonucleotides 
coding for miR-16, miR-16 + 1 base, and miR-16 + 15 bases, respectively. The CT 
values of the detection of miR-16 + 1 base and miR-16 + 15 bases at 3’ end were 
about 1.8 and 13.9 CT, respectively, delayed, compared with that of miR-16 without 
any base extension (Figure 4.4). 
To evaluate the specificity of the assay for the the mature miRNA sequence, rather 
than any fragmented genomic DNA, I subjected 4 aliquots of an RNA preparation to 
no treatment or treatment by DNase I and/or RNase A. With no treatment, miR-141 
was readily detected in this RNA preparation. However, with RNase A treatment, it 
was shown that no or extremely low quantities of miR-141 could be detected. The 
presence of DNase I treatment did not largely affect the quantities of miR-141, 
compared to the corresponding treatments without DNase I. The data suggested that 
the two-step QRT-PCR assays were truly RNA-specific (Table 4.2). 
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Figure 4.2 Two-step QRT-PCR for miR-16. 
(A), amplification plots obtained using two-step QRT-PCR for the miR-16 RNA 
oligonucleotide. Each plot corresponds to a particular input target quantity (copies/ 
I^L), marked by a corresponding symbol. The x axis denotes the cycle number of the 
two-step QRT-PCR. The y axis denotes the ARn, which is the fluorescence intensity 
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over the background. (B), plot of the threshold cycle (CT) against the input target 
quantity (common log scale). The correlation coefficient was 0.99. 
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Figure 4.3 Calibration curves of two-step QRT-PCR for miR-16 using RNA and 
DNA oligonucleotides. 
(A), plot of the threshold cycle (CT) against the input target quantity (common log 
scale) using RNA oligonucleotide of miR-16 as a calibrator. The correlation 
coefficient and gradient were 0.99 and -3.55, respectively. (B), plot of the threshold 
cycle (CT) against the input target quantity (common log scale) using DNA 
oligonucleotide of miR-16 as a calibrator. The correlation coefficient and gradient 
were 0.99 and -3.56, respectively. 
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Figure 4.4 Two-step QRT-PCR assays on DNA oligonucleotides coding for 
miR-16 without any base extension, with 1 base extension and with 15 bases 
extension at the 3，end. 
Amplification plots obtained using two-step QRT-PCR for the 3 DNA 
oligonucleotides. Each plot corresponds to a particular input oligonucleotide, that 
code for miR-16, miR-16 + 1 base and miR-16 + 15 bases at the 3，end. Each of the 
plots is marked by a corresponding symbol. The x axis denotes the cycle number of 
the two-step QRT-PCR. The y axis denotes the delta Rn, which is the fluorescence 
intensity over the background. 
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Table 4.2 Quantities of miR-141 remained after RNA sample was subjected to 
different combinations of DNase I and/or RNase A treatments. 
Enzyme treatments Quantities of miR-141 
DNase I RNase A (copies/ng) 
Treatment 1 ^ 3 
Treatment 2 ^ 0 
Treatment 3 < 2060 
Treatment 4 2254 
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4.3.2 Detection of cell-free miRNA in maternal plasma 
Plasma samples from 20 pregnant women in the third trimester of pregnancy were 
measured for cell-free miR-16. Cell-free miR-16 was detected in all 20 maternal 
plasma samples being tested. The median concentration of plasma cell-free miR-16 
was 2.7 X 10^  copies/mL (interquartile range, 2.4 x 10^-6.2 x 10^  copies/mL). 
To assess the precision of the whole analytical procedure, including the RNA 
extraction, reverse transcription, and amplification steps, a randomly chosen plasma 
sample was divided into 18 aliquots for 18 replicated RNA extractions and two-step 
QRT-PCR assays. The CV% for the CT value was 1.1 % (Mean土SD, 22.9±0.3) for 
this analytical system involving RNA extraction and miRNA quantification. 
4.4 Discussion 
Previously, the detection of cell-free mRNA transcripts in the plasma and serum of 
human individuals has already opened up many new diagnostic possibilities (Lo and 
Chiu 2007). Quantitative measurements of circulating placental mRNA transcripts 
have provided a noninvasive and, at that time, novel approach for the diagnosis of 
pathological conditions involving the quantitative aberrations of mRNA transcripts 
expressed in the placenta, such as pre-eclampsia (Ng et al 2003a) and fetal 
chromosome aneuploidies (Ng et al. 2004). In addition, this application of 
placental-specific mRNA represents a significant step towards the development of 
universal nucleic acid markers that can be used for all pregnant women, regardless of 
fetal gender and genetic polymorphisms. 
Recently, miRNAs are increasingly being recognized as important regulators of 
cellular and biological functions. In particular, aberrant expressions of miRNAs are 
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reported in pathological conditions such as cancers and developmental defects 
(Bartel 2004). Given the pseudomalignant nature of the human placenta, one may 
wonder i f placental miRNAs would, like DNA and mRNA, be released into maternal 
plasma. This hypothesis, i f proven to be true, may provide a novel class of universal 
nucleic acid markers that is also not limited by fetal gender and genetic 
polymorphisms for noninvasive prenatal diagnosis. However, previously, whether 
miRNAs are present in maternal plasma, and even i f they are present, whether they 
are stable enough for robust detection in human plasma have remained unexplored. 
In this part of the thesis, I have demonstrated that one miRNA, miR-16, does exist 
and exists at such a high concentration in maternal plasma that robust extraction and 
detection can be achieved. 
The first part of this study aimed to develop and to evaluate an approach for the 
quantification of miRNAs. Using the mature miR-16 sequence as a target, I 
developed a two-step QRT-PCR system from the TaqMan® MicroRNA Assay 
(Applied Biosystems) which was originally designed for relative quantification of 
miRNAs. The data demonstrated that the two-step QRT-PCR system could detect 
over a dynamic range of over 9-log difference with a correlation coefficient of 0.99. 
The detection by two-step QRT-PCR was highly precise with a CV% for CT as low as 
0.53%. I also demonstrated the specificity of the system. The data showed that the 
assay could differentiate a target with even a single base extension on its 3’ end. It 
was also capable of targeting miRNA sequences, but not fragmented genomic DNA 
contamination carried over from the RNA extraction. 
In addition, because the TaqMan® MicroRNA Assay (Applied Biosystems) involves 
the use of rMoMuLV which can reverse transcribe both DNA and RNA 
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oligonucleotides, I further investigated i f both DNA and RNA oligonucleotides were 
suitable to be used as calibrator to produce similar PCR efficiencies. The use of DNA, 
instead of RNA, oligonucleotides as calibrators would greatly reduce the cost of the 
experiments, especially in the subsequent larger-scale experiments as described in 
Chapter 5. The data revealed similar PCR efficiencies of the RT-PCR assays when 
using either DNA or RNA oligonucleotides as calibrators. Hence the use of DNA 
oligonucleotides as calibrators would help reducing cost, by about 6-fold, of the 
subsequent studies, but maintaining the accuracy of the results. 
In the second part of this study, I further sought to evaluate the possibility of plasma 
miRNA analysis. Using a column-based RNA extraction protocol for RNA extraction 
(Chapter 3.1) and the two-step QRT-PCR system, I demonstrated, for the first time, 
that miRNAs could be detected in maternal plasma. MiR-16 was chosen as the target 
of this initial evaluation because it was found to be a highly and ubiquitously 
expressed miRNAs, especially in blood cells. I reasoned that such a high level in 
blood cells, which is in close contact with the plasma, would provide a higher chance 
of being detected. The median concentration of miR-16 in plasma was 2.7 x ICT 
7 7 
copies/mL (interquartile range, 2.4 x 10 -6.2 x 10 copies/mL). This analytical 
system involving both RNA extraction and miRNA quantification was shown to have 
a CV% for CT of 1.1 %. Such a high concentration of miR-16 and the highly reliable 
analysis make plasma miRNA analysis practical for the further development as 
bio-markers for diagnostic purposes. In particular, because the aberrantly lowered 
levels of miR-16 were repeatedly reported in the bloods cells of patients with chronic 
leukemia lymphoma (CLL) (Calin et al 2002, Calin et al. 2005), the detection of 
miR-16 in plasma may have broader implications in the field of CLL diagnosis and 
monitoring. It would be interesting to compare i f miR-16 concentration in the 
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cell-free portion of plasma might be different compared to that in the leukocytes of 
these patients. It would also be interesting to see i f plasma concentration of miR-16 
might have any diagnostic or prognostic potential in CLL. Furthermore, i f the 
aberrant expression of miR-16 can be generalized to other hematological cancers, 
then a new approach for studying and assessing hematological cancers may be 
possible. 
In this study, to enhance the extraction of small-RNAs, I employed a RNA extraction 
protocol (Chapter 3.1) based on that developed by Ng et al. (2002). The major 
difference is the use of a column-based RNA isolation protocol of mirVana'^^ 
miRNA Isolation Kit (Ambion) in my current protocol. Unlike other RNA extraction 
columns which were unable to retain small RNA below 200 nucleotides long, the 
filter cartridge (Ambion) was specially designed for the purification of small RNAs, 
including miRNAs, which were only about 21-25 bases long. My protocol involved 
an organic extraction using TRIzol® or TRIzol® LS reagent (Invitrogen) followed by 
the immobilization of RNA on glass-fiber filters designed for purifying small RNAs 
using a micro spin protocol for the subsequent steps. 
In conclusion, this part of the study has described the development and evaluation of 
a highly accurate and quantitative approach for the analysis of plasma miRNAs. 
Moreover, I was the first to demonstrate the presence of cell-free miRNAs in 
maternal plasma. These novel discoveries have further broadened the potential 
applications of circulating nucleic acids in maternal plasma for noninvasive prenatal 
diagnosis. However, these results were generated mainly on a miRNA ubiquitously 
expressed by all human tissues. Further investigations on the possibility of detecting 
miRNAs released by the placenta into maternal plasma were conducted in Chapter 5. 
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CHAPTER 5: SYSTEMATIC IDENTIFICATION AND 
CHARACTERIZATION OF PLACENTAL MICRORNAS IN 
MATERNAL PLASMA 
5.1 Introduction 
The successful extraction and detection of circulating cell-free miRNAs in maternal 
plasma offer new possibilities for noninvasive prenatal investigation. In Chapter 4, it 
was shown that, with an ubiquitously and highly expressed miRNA, miR-16, 
circulating cell-free miRNA from plasma could be robustly extracted using a newly 
devised plasma RNA extraction protocol (Chapter 3.2.1) and be accurately quantified 
by two-step QRT-PCR assays. 
The next step towards developing circulating miRNA as a tool of noninvasive 
prenatal investigation is to search for placental miRNAs in the plasma of pregnant 
women using techniques as described in Chapter 4. Previously, the placenta has been 
shown to release its mRNA transcripts into maternal plasma (Ng et al 2003b). Here, 
I hypothesized that the placenta would also release its miRNA into maternal plasma, 
so I systematically studied the levels of 157 miRNAs, the miRNA assays of which 
were available in the TaqMan® MicroRNA Assays Early Access Kit - Human Panel 
(Applied Biosystems), in the placenta. Furthermore, in another previous study, the 
hematopoietic compartment was shown to be the predominant source of circulating 
DNA in the plasma of non-pregnant individuals (Lui et al 2002). Here, I also 
hypothesized that the maternal blood cells would be the predominant source of 
non-placental miRNA in maternal plasma. So I studied and compared the miRNA 
profile from maternal blood cells, and selected only those miRNAs that were 
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expressed in the placenta at much higher levels than in maternal blood cells for 
further analysis. Ideally, fetal-derived markers in maternal plasma should be cleared 
after delivery of the fetus. So I further narrowed down my systematic search to 
include only those miRNAs that were not detectable in maternal plasma collected 24 
hours after delivery (Tsui et al 2004). 
Novel miRNAs are being discovered continuously. In May 2007, 475 mature miRNA 
sequences were recorded in the Sanger Center MicroRNA Registry, Release 9.2 
(Griffiths-Jones et al. 2006). Since the functions of most miRNAs remain unexplored, 
it would be difficult to use a "candidate transcript" approach, as in the discovery of 
circulating fetal mRNAs (Ng et al 2003b). Instead, I systematically screened for 
placental miRNAs in maternal plasma using the two-step QRT-PCR assays with 157 
assays available in the TaqMan® MicroRNA Assays Early Access Kit — Human Panel 
(Applied Biosystems). This strategy would systematically identify placental miRNAs 
detectable in maternal plasma. I hope that the results of this study can provide 
quantitative information for evaluating the potential use of placental miRNAs in 
maternal plasma for noninvasive diagnostic tests of pregnancy-associated disorders. 
This part of the thesis aims to search for and to characterize placental miRNAs in 
maternal plasma for future use in prenatal diagnosis. Firstly, using TaqMan® 
MicroRNA Assays, I systematically screened for placental miRNAs in maternal 
plasma. Secondly, I sought to decipher the biological properties, such as the temporal 
profile of placental miRNA concentration in maternal plasma during the three 
trimesters of pregnancy, and the physical properties, such as the possible association 
with particulate matter and stabilities of purified miRNA compared to purified 
mRNA in plasma. Such fundamental information on placental miRNA in maternal 
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plasma would form the ground work to further develop them into noninvasive 
biomarkers for prenatal monitoring. 
5.2 Materials and methods 
5.2.1 Sample collection 
Peripheral blood samples were collected from pregnant women, with singleton, 
uncomplicated pregnancies, just before and at 24 hours after elective caesarean 
delivery. Paired term placental tissues were also collected just after the delivery. For 
the module studying the temporal profile of placental miRNA concentration in 
maternal plasma, peripheral blood samples were collected from 10 first-trimester 
(gestational age range: 12-14 weeks), 10 second-trimester (gestational age range: 
17—19 weeks), and 10 third-trimester (gestational age range: 37-39 weeks) 
pregnancies. In addition, peripheral blood samples were collected from a healthy 
male with informed consent to test the stability of purified placental mRNA and 
miRNA in plasma (Chapter 5.2.2). Al l the samples were processed using the protocol 
described in Chapter 3.1. All pregnant women were recruited with informed consent 
for the Department of Obstetrics and Gynecology, Prince of Wales Hospital, Shatin, 
Hong Kong. The study was approved by the Joint Chinese University of Hong 
Kong 一 New Territories East Cluster Clinical Research Ethics Committee. 
5.2.2 Experimental design 
Identification of placental miRNAs in maternal plasma 
In the first part of this study, I sought to identify cell-free placental miRNAs in 
maternal plasma from a panel of 157 miRNAs. The 157 assays were supplied as the 
TaqMan® MicroRNA Assays Early Access Kit — Human Panel (Applied Biosystems). 
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In brief, paired samples of pre-delivery maternal plasma and blood cells, 
post-delivery maternal plasma and placental tissue from five healthy pregnant 
women were tested for the concentrations of each of the 157 miRNA targets using 
two-step QRT-PCR assays as described in Chapter 3.3.3.3. The standard curve was 
constructed using serial dilutions of synthetic DNA oligonucleotide (Proligo) on each 
target miRNA with concentrations ranging between 6.25 x 10^  and 62.5 copes per RT 
reaction. By using a systematic screening strategy outlined in Figure 5.1, placental 
miRNA in maternal plasma were identified. 
Detection rates and clearance kinetics of placental miRNAs in maternal plasma 
Detection rates, which are the percentages of the cases with detectable amount of the 
respective miRNAs, and clearance kinetics of placental miRNAs, identified as 
potentially detectable in maternal plasma in the previous part, were further 
investigated. Since a smaller number of miRNAs were to be investigated in detail, I 
studied them using more concentrated RNA preparations extracted from the same 
volume of maternal plasma. In this part, total RNA extracted from 1.6 mL of plasma 
were eluted into 20.35 fiL RNA solution. In contrast, in the screening of the previous 
part, the extracted total RNA was further diluted to 132 fiL, so that more miRNA 
assays could be performed initially. Paired pre- and 24-hour post-delivery maternal 
plasma from 10 healthy pregnant women (gestational age, 37—40 weeks) were 
measured for the concentrations of each of the candidate miRNA targets using 
two-step QRT-PCR systems as described in Chapter 3.3.3.3. 
Investigation on the effects of filtration on the concentrations of placental miRNA 
and mRNA transcript in maternal plasma 
Since the placental miR-141 was most readily detectable in maternal plasma with the 
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highest detection rate and concentrations among the miRNAs investigated, it was 
chosen for further characterization. To study i f this circulating placental miR-141 and 
hPL mRNA were particle-associated, I passed maternal plasma through filters of 
different pore sizes, and quantifying the concentrations of miR-141 and hPL mRNA 
in the filtrate. Plasma samples of 15 healthy women in their third trimester of 
pregnancies (gestational age, 38-40 weeks) were collected. Each plasma sample was 
divided into four aliquots: three were individually passed through filters (Millex-GV, 
Millipore, MA) with pore sizes of 0.22, 0.45 and 5 jum. The remaining aliquot was 
not subjected to any filtration. The miR-141 concentration in each of the processed 
sample was measured using two-step QRT-PCR assays as described in Chapter 
3.3.3.3. 
Stability o f puri fied placental miRNA and RNA in plasma 
The stability of exogenously added, purified, placental miRNA and mRNA in plasma 
was studied and compared. Two hundred and twelve nanograms of placental RNA, 
extracted as described in Chapter 3.2.1, were added to each of the six 0.8-mL aliquot 
of plasma obtained from a randomly selected, healthy, male human subject and were 
incubated for 0 s, 5 s, 15 s, 60 s, 1 hr, and 2 hr at room temperature. A control plasma 
sample without RNA added was included. After incubation, 1 mL of TRIzol® LS 
reagent (Invitrogen) was immediately added to stop the ribonuclease activity in blood. 
The plasma samples were measured for hPL mRNA and miR-141 concentrations 
with QRT-PCR as described in Chapter 3.3.2.2 and 3.3.3.3, respectively. The 
amounts of mRNA and miR-141 remaining in the plasma after the incubation were 
expressed as percentages relative to their corresponding starting concentrations at 0-s 
incubation time. 
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Temporal profile of circulating placental miRNA in maternal plasma during 
presnancy 
To study the gestational variation of the plasma concentration of the placental 
miR-141, peripheral blood samples were obtained from 30 pregnant women at 
various stages of gestation, in which 10 women were at the first trimester (gestational 
age, 12-14 weeks), 10 women were at the second trimester (gestational age, 17-19 
weeks) and 10 women were at the third trimester (gestational age, 37—39 weeks). The 
miR-141 concentration in each of the processed sample was measured using the 
two-step QRT-PCR assay as described in Chapter 3.3.3.3. 
5.2.3 RNA extraction and miRNA quantification 
Processing of peripheral blood samples and placental tissue for cell-free plasma 
followed procedure as described in Chapter 3.1. Two-step QRT-PCR assays for 
miRNAs quantification followed the procedures as described in Chapter 3.3.3.3. 
TaqMan® MicroRNA Assays of miRNAs were ordered from Applied Biosystems. 
Serial dilutions of synthetic oligonucleotides were used for the absolute 
quantifications of the miRNAs. 
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Figure 5.1 Schematic diagram of the strategy used for the systematic 
identification of placental miRNAs in maternal plasma. 
Paired placental tissues and maternal blood cell samples were collected and subjected 
to two-step QRT-PCR assays. MiRNAs expressed in the placenta at 10-fold or higher 
levels than in maternal blood cells were selected. Paired pre- and post-delivery 
plasma samples were collected and subjected to the two-step QRT-PCR assays. Since 
I aimed to identify candidate miRNA markers in plasma for pregnancy, the miRNAs 
that were not detectable in post-delivery maternal plasma were listed in bold in Table 
5.1. 
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5.3 Results 
5.3.1 A systematic search for placental miRNAs in maternal plasma using 
two-step QRT-PCR assays 
In this study, I employed a strategy as outlined in Figure 5.1 to identify candidate 
miRNA markers in maternal plasma. The levels of each candidate miRNAs in five 
cases of paired sample of pre-delivery plasma, 24-hour post-delivery plasma, 
placental tissue and maternal blood cells were obtained by the two-step QRT-PCR 
assay, as described in Chapter 3.3.3, for analysis. 
Previously, Lui et al. (2002) showed that the hematopoietic compartment was the 
predominant source of circulating DNA in the plasma of non-pregnant individuals. 
Based on this observation, Tsui et al. (2004) further hypothesized that much of the 
background maternal mRNA in maternal plasma also originated from the 
hematopoietic compartment, while the fetal mRNA mainly originated from the 
placental tissue. Here, I hypothesized that miRNAs expressed in the placenta would 
also give rise to the fetal-derived miRNAs amongst the background of maternal 
blood cells-dervied miRNAs in the maternal plasma. Because the aim of this part of 
the thesis is to identify placental miRNAs in maternal plasma, I systematically 
identified candidate miRNAs that have much higher levels in placental tissue than in 
paired maternal blood cells using 157 miRNA assays. Thus, 34 miRNAs that were 
expressed with at least 10-fold higher levels in placental tissue than in maternal 
blood cells were shortlisted (Table 5.1). Moreover, using the sensitive and 
quantitative QRT-PCR assays and with the reasonably high concentration of miRNAs, 
quantitative data on the presence of these target miRNA in pre- and 24-hour 
post-delivery plasma were also generated. Among them, 17 miRNAs were further 
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shortlist because they were completely undetectable in any 24-hour post-delivery 
maternal plasma samples collected from the five pregnancies. This panel represents 
the placental miRNAs that can be potentially developed as markers in maternal 
plasma for the noninvasive monitoring of pregnancy. 
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Table 5.1 List of placental miRNAs that can be potentially developed as markers 
in maternal plasma for the noninvasive monitoring of pregnancy (Chapter 
5.3.1). 
Median 
concentration Detection rate (%) d 
(copies/ng) 
Placenta LFOW Pre-delivery Post-delivery 
eeiis change plasma plasma 
miR-hsa-125b 821926 9778 84.1 100 100 
miR-hsa-141# 760118 6565 115.8 40 0 
miR-hsa-125a 539358 7852 68.7 100 100 
miR-hsa-100 339088 5794 58.5 100 100 
miR-hsa-99a 208557 3314 62.9 80 80 
miR-hsa-200c 178648 2365 75.5 100 40 
miR-hsa-205 39828 0$ N/A 100 60 
miR-hsa-135b # 34684 0$ N/A 0 0 
miR-hsa-224 20908 1235 16.9 60 80 
miR-hsa-149 # 14986 0$ N/A 0 0 
miR-hsa-127 13630 641 21.3 20 40 
miR-hsa-299-5p # 11452 359 31.9 20 0 
miR-hsa-154* # 10904 559 19.5 0 0 
miR-hsa-34c 9145 0$ N/A 0 0 
miR-hsa-214 9086 48 189.3 60 100 
miR-hsa-34a 8679 808 10.7 40 80 
miR-hsa-133a 6084 386 15.8 20 80 
miR-hsa-218 5723 381 15.0 0 40 
miR-hsa-200b 4088 392 10.4 0 0 
miR-hsa-139 3919 0$ N/A 0 0 
miR-hsa-133b 3891 290 13.4 100 100 
miR-hsa-154 3408 207 16.5 0 0 
miR-hsa-203 3404 0$ N/A 20 20 
miR-hsa-323 2675 121 22.1 20 20 
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miR-hsa-368 1895 84 22.6 0 0 
miR-hsa-373 1895 73 26.0 0 0 
miR-hsa-137 1871 0$ N/A 0 0 
miR-hsa-184 1771 109 16.2 0 0 
miR-hsa-372 957 0$ N/A 0 0 
miR-hsa-371 412 0$ N/A 0 0 
miR-hsa-211 379 0$ N/A 20 20 
miR-hsa-34b 332 30 11.1 0 0 
miR-hsa-337 84 0$ N/A 0 0 
miR-hsa-198 37 0$ N/A 20 20 
a Names of the 17 microRNAs which were undetectable in 24-hour post-delivery plasma are shown in 
bold. 
b Placental microRNAs chosen for further characterization in maternal plasma were marked with (#). 
Concentrations of samples without amplification signal detected were referred to as 0 copies/mL or 0 
copies/ng ($). 
e MiRNAs are sorted in descending order of the median concentration in the placenta, 
d Detection rate is the percentage of the number of cases with detectable amount of the respective 
miRNA. 
e Fold change is the ratio of the concentration of a miRNA in the placenta to that in the maternal blood 
cells. 
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5.3.2 Detection rate and clearance kinetics of placental miRNAs in maternal 
plasma 
The detection rates, which are the percentages of the cases with detectable amount of 
the respective miRNAs, and clearance kinetics of some of the candidate miRNA 
markers for pregnancy in maternal plasma were further analyzed. Among the panel 
identified systematically in the previous section, the five miRNAs most highly 
expressed in the placenta and undetectable in any of the five post-delivery maternal 
plasma samples were chosen for further investigation. The reason behind this choice 
was based on our previous experience with placental mRNA transcripts in maternal 
plasma. Those mRNA transcripts that were most highly expressed in the placenta 
were also most readily detectable in maternal plasma. As an extrapolation of this 
concept, I presumed the most highly expressed miRNA in the placenta would also be 
the most readily detectable in maternal plasma. 
Among the 10 pregnant women recruited for this part of the study, miR-141 was 
100% detectable in the pre-delivery plasma but only in 50% detectable in the 24-hour 
post-delivery plasma, with median concentrations of 4391 (interquartile range: 
1576-8279 copies/mL) and 241 copies/mL (interquartile range: 0-1323 copies/mL)， 
respectively (Figure 5.2A). A statistically significant decrease in maternal plasma 
miR-141 concentration was observed before and after delivery (Wilcoxon test, P = 
0.003). MiR-135b was 20% detectable in the pre-delivery plasma but undetectable in 
any 24-hour post-delivery plasma, with the median concentration of 0 (interquartile 
range: 0-0 copies/mL) in the pre-delivery plasma (Figure 5.2B). No systematic 
alteration in maternal plasma miR-135b concentration was observed before and after 
delivery (Wilcoxon test, P = 0.5). MiR-149 was 80% detectable in the pre-delivery 
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plasma but undetectable in any 24-hour post-delivery plasma, with the median 
concentration of 594 (interquartile range: 336-893 copies/mL) in the pre-delivery 
plasma (Figure 5.2C). A statistically significant decrease in maternal plasma 
miR-149 concentration was observed before and after delivery (Wilcoxon test, P = 
0.003). MiR-299-5p was 50% detectable in the pre-delivery plasma but only 20% 
detectable in the 24-hour post-delivery plasma, with median concentrations of 225 
(interquartile range: 0-553 copies/mL) and 0 copies/mL (interquartile range: 0-0 
copies/mL), respectively (Figure 5.2D). No systematic alteration in maternal plasma 
miR-299-5p concentration was observed before and after delivery (Wilcoxon test, P 
二 0.063). MiR-154* was undetectable in any pre-delivery plasma and 24-hour 
post-delivery plasma even with the more concentrated plasma RNA input (Figure 
5.2E). As a control, detection of miR-29a was performed alongside with each sample 
to show that the extraction methods worked well for all samples. MiR-29a was 
chosen because it was detected at similarly high levels in both pre- and post-delivery 
plasma. MiR-29a was detected in all pre- and 24-hour post-delivery plasma samples 
with median concentrations of 40559 (interquartile range: 27178-50614 copies/mL) 
and 34667 copies/mL (interquartile range: 31018-40594 copies/mL), respectively 
(Figure 5.2F). No systematic alteration in maternal plasma miR-29a concentration 
was observed (Wilcoxon test, P = 0.274), as expected for such control miRNA. 
In summary, 4 out of 5 of the placental miRNA investigated in this part were 
detected in maternal plasma at higher detection rates and at higher median 
concentrations before delivery, compared to those after deliveries. It showed their 
association with pregnancy and thus they were potentially applicable for use in 
prenatal monitoring. 
98 
Placental micro RNAs in maternal plasma 
The low detection rates of miR-135b and miR-299-5p and miR-154* indicated that 
there were still rooms for improvement in the miRNA extraction and miRNA 
quantification. 
5.3.3 Effects of filtering maternal plasma on the concentration of placental 
miRNA and mRNA 
Since miR-141 was the most readily detectable in maternal plasma, I sought to 
further characterize its nature. To decipher the physical nature of this placental 
miRNA in maternal plasma, I filtered 0.8 mL aliquots of maternal plasma from 15 
pregnant women through filters with pore sizes of 5 jam, 0.45 |Lim and 0.22 jiim, 
quantified the concentration of this placental miR-141 in the filtrate, and compared 
with that without filtration. No statistically significant difference was found in the 
concentration of miR-141 among plasma samples filtered through different-sized 
pores (Friedman test, P = 0.257，Figure 5.3A). The median concentrations of 
miR-141 were 6082 copies/mL (interquartile range: 4211-8803 copies/mL), 7317 
copies/mL (interquartile range: 5669-11087 copies/mL), 6115 copies/mL 
(interquartile range: 4779-10264 copies/mL), and 5472 copies/mL (interquartile 
range: 4536-10123 copies/mL) in plasma unfiltered, filtered through 5-, 0.45-, and 
0.22-|Lim filters, respectively. Hence, these data suggested that placental miR-141 in 
maternal plasma was not associated with subcellular particles > 0.22-jim in diameter. 
In contrast to these miR-141 results, with the same experiment, the median 
concentrations of hPL mRNA were 980 copies/mL (interquartile range: 536-2193 
copies/mL), 834 copies/mL (interquartile range: 0-1226 copies/mL), 0 copy/mL 
(interquartile range: 0-0 copy/mL), and 0 copy/mL (interquartile range: 0-605 
copies/mL) in plasma unfiltered, filtered through 5-, 0.45-, and 022-\xm filters, 
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respectively. These data show that filtration caused a clearly observable reduction in 
hPL mRNA concentrations in plasma samples (Friedman test, P < 0.05，Figure 5.3B). 
Pair-wise analysis further indicated that statistically significant differences were 
detected in every pair of these filter sizes (Student-Newman-Keuls Method, P < 0.05 
for each pair). In paired plasma samples with detectable hPL concentration, the 
median concentration was reduced by 1.82-fold as the plasma sample was passed 
through 5 |Lim-filters, and was further reduced by 1.69-fold as they were passed 
through 0.45 ^im-filters (Table 5.2). The plasma hPL mRNA concentration decreased 
to undetectable level after the plasma had been filtered through the 0.22 jLim filters. 
This is consistent with the previously published results on the particle-associated 
nature of hPL mRNA in maternal plasma (Tsui et al 2002). 
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Table 5.2 Folds of reduction in hPL mRNA concentrations when plasma was 
passed through filters of different pore sizes. 
Filtered samples (filter pore size) 
Overall reduction 
5 |Lim 0.45 )am 0.22 |Lim 
hPL mRNA 1.82-fold 1.69-fold - -
The reduction-fold was calculated by dividing the m R N A level of a sample passing through a particular 
size filter, by the m R N A levels of the same sample passing through a filter in the next (bigger) size 
category. 
For paired samples with detectable concentration of hPL, the median of the folds of reduction was shown. 
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5.3.4 Stability of purified placental mRNA and miRNA in plasma 
It was surprising that miRNA, being RNA in nature, existed in plasma at reasonably 
high concentration seemingly without any protection, such as association with 
subcellular particles, from RNase activities in blood. Intrigued by this surprising 
observation, I proposed that miRNA might be intrinsically more stable than mRNA 
transcripts in its purified, naked form, without any association with particles or 
proteins, in plasma. To explore this proposed idea, I exogenously added purified 
RNA sample, extracted as described in Chapter 3.2.1, into the plasma sample from a 
randomly chosen healthy male, incubated for different time points, and quantified for 
the concentration of miR-141 and hPL mRNA remaining after incubation. Without 
any exogenously added placental RNA, there was no detectable concentration of 
miR-141 and hPL in the male plasma as expected (Figure 5.4B). With the addition of 
purified placental RNA, within the first 15 s, the miR-141 concentration decreased 
by 24-fold from 100% (1.3 x 10^  copies/mL) to 4.1% (5.5 x lO* copies/mL) relative 
to its starting concentration at 0-s incubation (Figure 5.4B). With a 60-s or up to 2-h 
incubation, the concentration of miR-141 was observed to remain at about 1% (about 
10,000 copies/mL). In contrast, within the first 15 s, hPL mRNA transcript was 
shown to decrease more dramatically for 333-fold from 100.0% (5.5 x 10^  copies/mL) 
to 0.3% (1539 copies/mL) relative to its starting concentration at 0-s incubation 
(Figure 5.4B). With a 60-s or longer incubation, no hPL mRNA could be amplified. 
This experiment was repeated with lower and higher amounts of incubated placental 
RNA (106ng, 425 ng, 825 ng) to ensure that such effect was not dependent on the 
amount of the exogenously added RNA, and similar results were obtained for both 
miR-141 and hPL (Figure 5.4A, C and D). 
In summary, purified miR-141 was degraded at a much slower rate than that of 
102 
Placental micro RNAs in maternal plasma 
purified hPL mRNA in plasma in the first 15 s. Furthermore, purified miR-141, in the 
absence of any association with subcellular particles or proteins, still remained 
detectable in plasma for over 2 hours. 
5.3.5 Temporal profile of placental miRNA concentrations in maternal plasma 
across different trimesters of pregnancies 
The placental miR-141 was measured in the plasma of 10 pregnant women each 
recruited from the first, second and third trimesters of pregnancy (Table 5.3). 
MiR-141 was 80% detectable in maternal plasma of the first-trimester and 100% 
detectable in maternal plasma of both the second and the third trimesters. The median 
miR-141 concentrations were 7756 copies/mL (interquartile range: 4065-9959 
copies/mL), 8761 copies/mL (interquartile range: 5378-17090 copies/mL), and 
19464 copies/mL (interquartile range: 18240-29852 copies/mL) for the first-, second-, 
and third-trimester maternal plasma, respectively. Overall, circulating miR-141 
concentration showed an increasing trend with gestational age (Spearman correlation 
analysis, r = 0.58, P = 0.00, Figure 5.5). 
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Table 5.3 Concentration of miR-141 in the plasma of pregnant women during 
the first, second, and third trimesters. 
miR-141 
ry, . . f. median concentration Trimester of pregnancy _ , , 丁� 
Detection rate (copies/mL) 
(interquartile range) 
‘ 80% 7,756 First 
(8/10) (4,065-9,959) 
。 1 100% 8,761 
Second 
(10/10) (5,378-17,090) 
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Figure 5.2 Clearance kinetics of candidate miRNA markers in maternal plasma 
for monitoring pregnancy. 
Concentrations of (A) miR-141, (B) miR-135b, (C) miR-149, (D) miR-299-5p, (E) 
miR-154*, and (F) miR-29a in maternal plasma before delivery and at 24 hr after 
delivery were quantified by the two-step QRT-PCR assays. Each line represents one 
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Figure 5.3 Concentrations of placental miR-141 and hPL mRNA transcripts in 
maternal plasma after filtration through filters of different pore sizes. 
(A), plasma hPL mRNA concentrations (copies/mL), as determined by QRT-PCR (y 
axis), and (B), plasma miR-141 concentrations (copies/mL), as determined by QPCR 
(y axis), were plotted against filter pore sizes (x axis). The lines inside the boxes 
denote medians. The boxes mark the interval between the and percentiles. 
The whiskers denote the interval between the and percentiles. # indicate 
data points outside the and percentiles. (N.B. Data are presented in the same 
format for all of the box plots in this thesis.) 
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Figure 5.4 Stabilities of purified, exogenously added, placental miRNA and 
mRNA transcripts in plasma. 
Percentage of hPL mRNA and miR-141, relative to their respective starting 
concentrations, remaining in plasma after incubation as determined by QRT-PCR 
assays are plotted on y axis. The incubation time are shown on the x axis. (A), (B), 
(C), and (D) are graphs correspond to the incubation of 106 ng, 212 ng, 425 ng, and 
825 ng, respectively, of total RNA being incubated. 
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Figure 5.5 Concentration of placental miR-141 in maternal plasma against 
gestational age. 
Concentration of miR-141 (copies/mL) in maternal plasma was shown to be 
correlated with the gestational age (weeks). 
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5.4 Discussion 
Chapter 4 showed that miRNAs do exist in the cell-free portion of plasma, and can 
be stably extracted and accurately quantified. Thus, these results have opened up 
opportunities for using miRNA in plasma as noninvasive markers. 
In the first part of this Chapter, I provided the first evidence that placental miRNAs 
can be detected in the maternal plasma. Data presented in this Chapter supports this 
hypothesis. Here, I screened for placental miRNAs in maternal plasma from a panel 
of miRNAs using the strategy as outlined in Figure 5.1. This strategy is based on 
previous findings that demonstrated the predominant hematopoietic origin of plasma 
DNA in normal individuals (Lui et al. 2002) and that the placenta is a major source 
circulating fetal mRNA in maternal plasma during pregnancy (Ng et al 2003b). 
Using two-step QRT-PCR assays for miRNAs quantification, I quantified the levels 
of each of the miRNAs available in the TaqMan® MicroRNA Assays Early Access 
Kit — Human Panel (Applied Biosystems). Out of the 157 miRNAs that were 
screened in this study, 34 of them had at least ten-fold higher levels in placenta than 
in maternal blood cells. Moreover, using highly sensitive and quantitative QRT-PCR 
assays and with the extremely high biological levels of miRNA, 17 miRNAs were 
further shortlisted because they were completely undetectable in 24-hour 
post-delivery plasma in their initial detections in maternal plasma. These shortlisted 
markers are potentially useful for monitoring pregnancy noninvasively. Since the 
functions of most of the miRNAs remain largely unexplored, I have applied this 
systematic search which required no prior knowledge of the miRNA function. 
Among the five placental miRNAs being studied in Chapter 5.3.2, each of them had 
a different detection rates, concentrations and clearance kinetics upon delivery from 
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one another. For example, in one of the placental miRNAs, miR-141, it was shown to 
be readily detectable in all three trimesters of pregnancy with the earliest detection in 
the 12th week of gestation. Its concentration is reasonably high and increases with 
gestational age. Moreover, its concentration decreases significantly (Wilcoxon test, P 
=0.003) with a median fold change of 5.3. However, it was noted that miR-141 did 
not show complete clearance from all pregnant women after delivery. A possible 
explanation for this is that miR-141 is being cleared from maternal plasma at 
different rates from different women. Nevertheless, such a robust detection of the 
miR-141 in maternal plasma made it potentially useful for the noninvasive 
monitoring of pregnancy. Similar investigation on the biology of other placental 
miRNA should be carried out to address their potentials. 
In subsequent parts of this study, I sought to characterize the various molecular 
characteristics of circulating placental miRNAs. MiR-141 was chosen as a target for 
the study because it has a higher plasma concentration than the other candidates on 
the list. 
Given the labile nature of RNA and the ribonuclease activity in the blood (Reddi and 
Holland 1976), exogenous and purified mRNA added to the plasma was degraded 
within seconds (Tsui et al. 2002). Surprisingly, circulating mRNA exists in detectable 
quantities in plasma. Tsui et al. (2004) demonstrated that such an exceptional 
stability was a result of the association between the mRNAs and subcellular particles. 
Because miRNA, like mRNA, was shown to be stably present in plasma and exists at 
an exceptionally high level, it raises the question of whether the stability of 
circulating miRNAs may also result from an association with subcellular particles. 
To address this problem, I performed a filtration study. The data clearly indicated that 
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filtration had no significant effect on the concentration of miR-141 in maternal 
plasma. These results demonstrated that miR-141 in plasma is not associated with 
subcellular particles with size larger than 0.22 /xm. In contrast, the hPL mRNA, 
which was studied in parallel as a control, demonstrated its association with 
subcellular-particles as described previously. In brief, the above results suggest that 
the exceptional stability of circulating miRNA is not a result of the association with 
subcellular particles. However, whether this exceptional stability of miRNAs is a 
result of association with particulate matter, such as protein factors and 
RNA-induced silencing complex, remains to be elucidated, perhaps by the use of 
ultra-centrifugation studies (Tsui et al. 2002). Moreover, an answer as to whether this 
special stability of miRNA is a general phenomenon awaits similar studies using 
other placental miRNA species. 
To further compare the stability of mRNA and miRNA in plasma, I performed a 
stability test. Extracted placental RNA was exogenously added and incubated in the 
plasma of a healthy male. Because extracted RNA is not associated with any 
subcellular or particulate matter, it is reasoned that the experiment will give a fair 
comparison of the stability of the two species of RNA as attributed to the length of 
the different species. Since there were no detectable concentrations of hPL mRNA 
and miR-141 in the male plasma, any hPL mRNA and miR-141 detected in this 
plasma sample were derived from the exogenously added placental RNA preparation. 
The data indicate that exogenous, purified miRNA added to the plasma was more 
resistant to degradation and remained at substantial concentration even after two 
hours of incubation, especially when compared with hPL mRNA. The explanation 
for these results is not clear at present. One possible explanation is that miRNAs may 
be too short to be further cleaved by ribonucleases in plasma, thus allowing them to 
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exist in particle-free form in plasma. Nonetheless, the exceptional stability of miRNA 
in plasma is a definite advantage for its potential application in noninvasive prenatal 
monitoring. 
In conclusion, the present study has demonstrated miRNAs as a potential novel class 
of gender- and polymorphism-independent pregnancy-associated markers in maternal 
plasma. They are not associated with subcellular-particle. Yet, they exist stably in 
plasma and could be detected quantitatively and robustly even after freezing, thawing 
and processing of clinical blood samples routinely. I have validated a method for the 
discovery of such miRNAs, and a list of such miRNAs has also been complied. With 
the help of higher throughput technologies, such as sensitive labeling and detection 
strategies for miRNA microarray (Wang et al. 2007), this search strategy wil l allow 
discovery of more placental miRNA in maternal plasma with diagnostic potential. 
They would facilitate the development of plasma miRNA as diagnostic markers. For 
example, with the recent demonstration of upregulated expression of miR-210 and 
miR-182 in preeclamptic placentas over gestational age matched normal placenta 
(Pineles et al 2007), it would be interesting to investigate i f the plasma concentration 
of these miRNAs would also be aberrantly represented. In addition, the 
demonstration of cell-free placental miRNAs in maternal plasma would initiate 
further investigations on its biological significance. Besides, as miRNAs derived 
from a tumor might analogously be released into the plasma, I believe that this study 
has opened up possibilities in the development of cell-free miRNAs in plasma for 
tumor diagnosis. 
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CHAPTER 6: HEMATOPOIETIC STEM CELL 
TRANSPLANTATION RECIPIENTS AS A MODEL TO STUDY 
CELL-FREE DNA IN URINE 
6.1 Introduction 
In recent years, the biology and diagnostic applications of cell-free DNA in plasma 
have attracted much research interest (Lo and Chiu 2007). In particular, Lo et al. 
(1999e) demonstrated the kinetics of rapid clearance of circulating fetal DNA in 
plasma after delivery of the fetuses. A number of hypotheses were raised to address 
the mechanism behind this phenomenon. One hypothesis was made by Botezatu et al. 
(2000). The group proposed that a portion of these cell-free DNA was cleared from 
the plasma as it passed through the kidney barrier into the urine. This group provided 
a number of evidences for this phenomenon. Firstly, in the urine of mice injected 
with human DNA, the Alu sequences, which is present only in the human genome, 
was successfully detected (Botezatu et al 2000). In addition, in women pregnant 
with male fetuses, male-specific sequences could be detected (Botezatu et al. 2000). 
They also detected, in the urine of cancer patients with colon adenocarcinoma, the 
cancer-associated K-ras mutations DNA sequences (Botezatu et al 2000). Since then, 
the term ‘transrenal-DNA, (Tr-DNA) has been coined to describe such DNA species 
which have been passed from the plasma into the urine through the kidney barrier. 
Transrenal DNA in urine is different from cell-free DNA in the urine which is 
derived from tumor of the urinary tract. In principle, the passage of these cell-free 
DNA molecules derived from tumors of the urinary tract does not require the 
transrenal passage of cell-free DNA. Of particular significance, Su et al. (2004b) 
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demonstrated that unfractionated human urine consists of both high-molecular 
weight DNA and low-molecular weight DNA. Upon centrifugation to remove cell 
debris, the concentration of low-molecular weight DNA was enriched in the 
supernatant fraction, while that of the high-molecular weight DNA was dramatically 
decreased (Su et al 2004b). Also, in about 83% of colorectal cancer patients, Y^-ras 
mutations concordant with those found in the primary tumours could be detected in 
the urine, and such ¥^-ras mutation sequences were abundant in the low-molecular 
weight DNA, but far less abundant in the high-molecular weight DNA isolated from 
the urine (Su et al. 2004b). Taken together, these data suggested that cell-free DNA 
species in the urine are short in size and were estimated to be about 150 to 250 bp in 
length (Su et al. 2004b). 
Independent studies were published reporting successful detections of male-specific 
DNA sequences in the urine of a proportion of pregnant women with male fetuses 
(Al-Yatama et al. 2001, Koide et al 2005), and hence lending further support to the 
transrenal DNA hypothesis. However, some investigator reported the inability to 
detect male-specific DNA sequences in women pregnant with male fetuses (Zhong et 
al. 2001a). In particular, the same group was also unable to detect these male-specific 
DNA sequences in pregnant women, who were suffering from pre-eclampsia, with 
male fetuses (Li et al. 2003). It was previously shown that in pregnant women with 
pre-eclampsia, elevated levels of fetal DNA in their plasma (Zhong et al. 2000) and 
increased renal permeability were observed. And proteinuria was one of the 
complications involved (Hayashi et al. 2002). Therefore, these reports concerning the 
inability to detect fetal DNA in urine of pregnant women have raised considerable 
doubts concerning the feasibility of Tr-DNA analysis. 
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In fact, several technical challenges have to be overcome to facilitate the successful 
detection of cell-free DNA populations, including Tr-DNA, in urine. Firstly, it has 
been reported that nucleases in urine reduces the efficiency of DNA analysis (Milde 
et al. 1999). Thus, ethylenediaminetetraacetic acid (EDTA) was added to reduce the 
activities of these divalent ion-dependent DNA nucleases. Secondly, cell-free DNA 
populations in the urine have been reported to contain a fraction of DNA species that 
are relatively short in size, roughly 150 to 250 bp (Su et al 2004b). Thus, 
investigators have proposed the use of special DNA extraction methods to retain 
these short DNA fragments (Su et al 2004a), which are often washed away as 
"impurities" in the most popular silica column-based DNA extraction kits. Moreover, 
PCR of short amplicon sizes are more preferred to long ones for DNA detection (Su 
et al. 2004a). Given all these technical considerations, there is currently no consensus 
method for processing and extracting DNA from urine. Subsequently, these factors 
have been hindering the understanding of cell-free DNA in urine. 
To gain more insights into the constituting components of cell-free DNA species, 
including Tr-DNA, in the urine, I analyzed them with molecular methods using the 
sex-mismatched hematopoietic stem cell transplantation (HSCT) recipients as a study 
model. Previous data have shown that following sex-mismatched HSCT, the ‘gender’ 
of the recipient's plasma DNA changed and resembled that of the donor (Lui et al. 
2002). For example, in female recipients of male stem cells, the median fractional 
concentration of donor-derived male DNA was 59.5% (interquartile range 42 to 65%), 
while her urinary tract would remain "female". This fractional concentration of 
donor-derived DNA in HSCT recipients was much higher than the mean fractional 
concentration of fetal DNA in maternal plasma, which was only 3.4% during weeks 
11 to 17 of gestation and 6.2% in the third trimester of pregnancy (Lo et al 1997)， 
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and less variable than that in plasma of cancer patients (Anker et al 1997). Thus, 
these results suggested that sex-mismatched HSCT may be a more powerful model 
system for the investigation on Tr-DNA because, as postulated by the phenomenon of 
Tr-DNA, donor DNA would be more readily detected in the urine of the HSCT 
recipients than in other transrenal models. It is hoped that this HSCT model can 
further our understanding of the molecular characteristics of cell-free urine DNA, 
including Tr-DNA, and hence facilitate the future development of cell-free urine 
DNA for noninvasive diagnosis. 
With a newly devised MassEXTEND™ assay accurately quantifying the fractional 
concentration of donor-derived DNA and a set of QPCR assays studying DNA size 
distribution, I dissected and observed that there are at least two sub-populations of 
cell-free DNA species in the urine. 
6.2 Materials and methods 
6.2.1 Sample collection 
Peripheral blood and urine samples were collected from 11 patients who suffered 
from hematological cancer or other hematological diseases and who received HSCT 
from donors of the opposite gender (Table 6.1). Al l the samples were prepared using 
the protocol described in Chapter 3.1. All patients were recruited with informed 
consent for the Department of Paediatrics, Prince of Wales Hospital, Shatin, Hong 
Kong. They were all in clinical remission from their respective diseases. The study 
was approved by the Joint Chinese University of Hong Kong — New Territories East 
Cluster Clinical Research Ethics Committee. 
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6.2.2 Experimental design 
Validation of the zinc fmser protein 2ene assay for determining the fractional 
concentrations of male DNA in a mixture of male and female DNA 
The zinc finger protein gene assay was designed as described in Chapter 3.4.2 to 
determine the fractional concentration of male DNA in mixtures of male and female 
DNA. To evaluate the precision of this assay, I replicated the quantification of 
fractional concentration of male DNA in urinary DNA from a healthy male subject 
for 20 times as described in Chapter 3.4.2. The analytical intrassay coefficient of 
variation percentage (CV%) of the fractional concentrations obtained was used as 
reference of analysis. 
To evaluate the quantitative linearity of the assay, a series of artificial DNA mixtures 
with different and known fractional concentrations of male DNA and female DNA 
were prepared. Fractional concentrations in different mixtures were measured using 
the assay as described in Chapter 3.4.2. The regression correlation coefficient {R^) of 
the measured and expected fractional concentrations in the mixtures was used as the 
reference of analysis. 
Fractional concentration of male DNA in peripheral blood cells, cell-free plasma, 
cell-free urine and urine cell pellets of sex-mismatched HSCT patients 
In order to decipher the constituting DNA components in urine using the 
sex-mismatched HSCT model, plasma, blood cells, urine and urine cell pellets from 
11 sex-mismatched HSCT patients were measured for the fractional concentrations 
of male DNA using the zinc finger protein gene assay as described in Chapter 3.4.2.1 
then performed statistical tests to show, i f there was any relationship between the 
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constituting components of different compartments. 
Size distribution of cell-free DNA in the plasma and the urine of sex-mismatched 
HSCT patients 
In order to analyze the size distribution of cell-free DNA molecules in the plasma 
and the urine, these bodily fluids were collected from 11 sex-mismatched HSCT 
patients. To measure the size distribution of the total population of cell-free DNA in 
these bodily fluids, the concentrations of the SRY (with amplicon sizes of 63, 107 and 
377 bp) and LEP (with amplicon sizes of 63, 105 and 356 bp) genes using QPCR 
assay as described in Chapter 3.3.4.2. This gave information of the cell-free DNA in 
urine in terms of the fragmentation of the cell-free DNA. The relative concentrations 
oi SRY and LEP gene in each sample were used for analysis of the size distribution 
of the cell-free DNA. The relative concentrations were calculated by dividing the 
absolute concentration of DNA determined by a real-time QPCR system for a 
particular amplicon size by the absolute concentration of DNA determined in the 
PCR system with the shortest amplicon used (Chan et al. 2004). In this study, the 
shortest amplicon used was 63 bp for both of the LEP and SRY genes. 
6.2.3 DNA extraction and quantification 
Processing of peripheral blood and urine samples for DNA followed the procedure as 
described in Chapter 3.1. Quantification of fractional concentration of male DNA 
followed the procedure as described in Chapter 3.4.2. Quantification of cell-free 
DNA of SRY and LEP genes of different amplicons size followed the procedure as 
described in Chapter 3.3.4.2. Serial dilutions of male blood cells genomic DNA with 
concentrations ranging between 0.78 and 10,000 genome equivalents per five 
microliters were used for construction of standard curve of absolute quantification of 
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6.3 Results 
6.3.1 Validation of the zinc finger protein gene assay 
In this study, the zinc finger protein gene assay was used to determine the fractional 
concentration of male DNA in mixtures of male and female DNA. This assay 
involves the use of a single PCR system to amplify the two homologues of the zinc 
finger protein gene located on the X- and Y-chromosomes, and generates two similar 
PCR products distinguishable by MALDI-TOF MS (Chapter 3.4.2). Compared to 
other analytical systems, in which one PCR system amplifies the male DNA and 
another one amplifies the female DNA, this analytical system maintains nearly 
identical PCR efficiencies in amplifying the X- and Y-chromosomes for estimating 
the male to female DNA ratio in term of fractional concentration of male DNA. Thus, 
the estimation is more accurate. Using this assay, the expected fractional 
concentration of a male DNA sample is 100% while that for a female DNA sample is 
0%. 
To assess the precision of the zinc finger protein gene assay, 20 replicated 
quantifications of the fractional concentration of male DNA in urine cell-free DNA 
from a healthy male subject were performed. The mean measured fractional 
concentration was 92% (mean 士 SD，92% 士 4o/o). The CV% for the fractional 
concentrations of these replicates was 4.9%. The assay showed a reasonably high 
precision in detection. 
To assess the quantitative linearity of this assay, a series of artificial DNA mixtures 
with known fractional concentrations of male DNA were analyzed using the zinc 
finger protein gene assay. When the expected and measured fractional concentrations 
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of male DNA were plotted against each other, the assay had an R^ of 0.99 and a slope 
of 0.96 (Figure 6.1). The assay was highly quantitative with a detection range of 
fractional concentration of male DNA between 0 and 100%. 
6.3.2 Fractional concentration of male DNA in blood cells and plasma of 
sex-mismatched HSCT patients 
Because this study involves the detection of donor-derived DNA in plasma and urine, 
I first demonstrated that the blood cells of all the HSCT recipients under study were 
completely donor-derived. This would facilitate the comparison of data between 
different subjects. As determined by the zinc finger protein gene assay, fractional 
concentration of male DNA in the blood cells of recipients showed that the "gender" 
of the blood cells of the recipients shifted completely to that of the donors. For 
example, in female recipients of male stem cells, the blood cells were shown to 
contain about 100% of male DNA and thus were mainly composed of male DNA; in 
male recipients of female stem cells, the blood cells were shown to contain about 0% 
of male DNA and thus were mainly composed of female DNA. This is consistent 
with the FISH results which showed that all blood cells in all the recipients were 
nearly 100% donor-derived (Table 6.1). Taken together, they showed that blood cells 
of all the HSCT recipients under this study were essentially completely 
donor-derived. 
Using the zinc finger protein gene assay, I illustrated the chimerism status of donor-
and recipient-derived cell-free DNA in the plasma of sex-mismatched HSCT 
recipients. It was previously shown that in HSCT recipients, majority of the cell-free 
DNA in plasma was donor-derived (Lui et al 2002) and a minority of the cell-fee 
DNA was recipient-derived (Lui et al. 2003). Thus, this part of the study aimed at 
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producing similar results to establish the feasiblility of using of this newly devised 
assay in DNA chimerism analysis. 
It was found that the median fractional concentration of male DNA in the plasma of 
the group of female recipients of male stem cells was 79.3 % (Figure 6.2A). In this 
group, the 79.3% of male DNA detected could only originate from the male blood 
cells. Therefore, this 79.3% represented the fraction of cell-free DNA originating 
from the hematopoietic system. The difference between the 79.3% in plasma and the 
100% as in donor-derived blood cells indicated that a portion of plasma DNA 
originated from the female nonhematopoietic cells of the recipients. 
In contrast, the median fractional concentration of male DNA in the plasma of the 
group of male recipients of female stem cells was 27.2% (Figure 6.2A). In this group, 
the 27.2% of male DNA of the cell-free DNA in the plasma represented DNA 
originating from the male nonhematopoietic cells and/or the remaining male 
hematopoietic cells of the male recipients. Because in all the patients under this study, 
essentially all of the blood cells were donor-derived, I could deduce that this 27.2% 
represented the percentage of cell-free DNA in the plasma originating from the male 
nonhematopoietic cells throughout the body. 
Taken together, these results were consistent with the previously published data 
which suggested that hematopoietic cells are the predominant source of cell-free 
DNA in plasma (Lui et al. 2002) while nonhematopoietic cells accounted for a 
minority of the cell-free DNA in plasma (Lui et al. 2003). These results also 
confirmed that the zinc finger protein gene assay could be used for study DNA 
chimerism. 
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6.3.3 Fractional concentration of male DNA in the urine and the urine eel且 
pellets of sex-mismatched HSCT patients 
I further sought to decipher the constituting components of cell-free DNA in the 
urine as derived from the donor and the recipient using the zinc finger protein gene 
assay. As shown in Figure 6.2B, the median fractional concentration of the male 
DNA in the urine of the group of female recipients of male stem cells was 38.3% 
while that for the group of male recipients of female stem cells was 92.3%. When 
comparing the median fractional concentrations of male DNA in the plasma and the 
urine, it was found that the fractional concentration of the recipient-derived DNA 
increased as the plasma passed through the kidney barrier into the urine. For example, 
in female recipients of male stem cells, there were 79.3% and 38.3% of male DNA in 
the plasma and the urine, respectively, representing a 2-fold increase in the fractional 
concentration of recipient-derived DNA in the urine than in the plasma; in male 
recipients of female stem cells, there were 27.2% and 92.3% of male DNA in the 
plasma and the urine, respectively. In other words, 72.8% and 7.7% of female DNA 
were detected in the plasma and the urine, respectively, and it represented a 9-fold 
increase in the fractional concentration of recipient-derived DNA in the urine than in 
the plasma. 
According to the hypothesis of Tr-DNA formation, Tr-DNA in urine is derived from 
cell-free DNA in plasma after it passes through the kidney barrier. I performed 
correlation tests to see i f there was correlation between the fractional concentrations 
of male DNA in the urine and those in the plasma. I f cell-free DNA in the urine is 
mainly Tr-DNA derived from cell-free DNA in the plasma, a significant correlation 
between the two groups would be expected. Table 6.2 summarizes the fractional 
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concentrations of male DNA in the plasma, urine and urine cell pellet. There was no 
significant correlation between the fractional concentrations of male DNA in the 
plasma and those in the urine (Spearman rank order correlation, r^  = -0.427, p = 
0.178 > 0.05, Figure 6.3 A). However, the fractional concentrations of male DNA in 
the urine and those in the urinary cell pellets showed a statistically significant 
correlation (Spearman rank order correlation, rs= 0.682, p = 0.0186 < 0.05，Figure 
6.3B). This data suggested the possible contribution of urine cell pellets to the urine 
cell-free DNA. Notably, it also provided a possible explanation for the much larger 
increase in the proportion of recipient-derived DNA in urine as cell-free DNA 
entered urine from plasma, in male recipients of female stem cells (9-fold increase) 
as compared with female recipients of male (2-fold increase) as described in the 
previous section. That is, the much longer urinary tract in male than in female might 
contribute to more recipient cells in the cellular portion of the urine. 
6.3.4 Size distribution of cell-free DNA in peripheral blood and urine samples of 
sex-mismatched HSCT patients 
To further decipher the constitution of cell-free DNA in the urine, I performed a 
series of real-time quantitative PCR assays to study the size distribution of cell-free 
DNA molecules in the urine. It was previously shown that majority of cell-free DNA 
molecules in plasma has less than 201 bp (Chan et al 2004). Therefore, i f cell-free 
DNA in the urine is derived from cell-free DNA in the plasma, it should also mainly 
consist of short DNA molecules. I f there is a substantial amount of cell-free DNA 
molecules in urine which is longer than 300 bp, they are probably released from the 
cellular portion of the urine. 
In this thesis, the real-time quantitative PCR assays were able to detect down to one 
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genome equivalent (GE) of the LEP gene or the SRY gene for all the amplicon sizes 
(Chan et al 2004). Because the absolute DNA concentrations vary widely between 
different individuals, I calculated the relative concentrations (Chapter 6.2.2) for each 
amplicon size so that the size distribution of DNA in each individual could be 
compared and summarized. 
For the cases with male donors to female recipients, the size distribution of cell-free 
DNA in the plasma and the urine were summarized in Table 6.3A. In the plasma, I 
observed that when the PCR amplicon size for LEP increased from 63 bp to 105 bp 
to 356 bp, its median concentrations, relative to the 63-bp amplicon, decreased from 
100% to 50.7% to 22.3% (median absolute concentration of LEP with the 63 bp 
assay was 184.7 GE/mL). This implied that the total, both donor- and 
recipient-derived, DNA molecules in cell-free plasma were mainly short DNA 
fragments. These data were consistent with the previous findings which showed that 
the majority (86%) of cell-free DNA in the plasma was smaller than 201 bp (Chan et 
al. 2004). In the urine, I observed that when the PCR amplicon size for LEP 
increased from 63 bp to 105 bp to 356 bp, its median concentrations, relative to the 
63-bp amplicon, similarly decreased from 100% to 93.0% to 43.9% (median absolute 
concentration of LEP with the 63 bp assay was 1775.6 GE/mL). Thus, the total, both 
donor- and recipient-derived, DNA molecules in cell-free urine were also mainly 
short DNA fragments. In particular, I observed that in both of the 105 bp and 356 bp 
LEP assays, the relative concentrations of all cases were higher in the urine (median, 
93.9% for the 105-bp amplicon and 43.9% for the 356-bp amplicon) than in the 
plasma (median, 50.7% for the 105-bp amplicon and 22.3% for the 356-bp amplicon). 
It showed that LEP DNA molecules, which represented both of the donor- and 
recipient-derived DNA, were relatively longer in the urine than in the plasma. 
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Moreover, because it has become previously thought that the size of Tr-DNA is 
mainly between 150 bp and 250 bp (Su et al 2004b), the existence of more 356 bp 
LEP DNA molecule in the urine than in the plasma suggested a release of these 
high-moleculer weight DNA into the urine from the cellular portion of the urine. 
In the plasma, I observed that when the PCR amplicon size for SRY increased from 
63 bp to 107 bp to 377 bp, its median concentrations, relative to the 63-bp amplicon, 
decreased from 100% to 55.4% to 0% (median absolute concentration of SRY with 
the 63 bp assay was 116.3 GE/mL). This implied that the donor-derived DNA 
molecules in cell-free plasma were mainly short DNA fragments. In the urine, I 
observed that when the PCR amplicon size for SRY increased from 63 bp to 107 bp 
to 377 bp，its median concentrations, relative to the 63-bp amplicon, similarly 
decreased from 100% to 83.8% to 15.6% (median absolute concentration of SRY 
with the 63 bp assay was 376.1 GE/mL). Thus, the donor-derived DNA molecules in 
the cell-free urine were also mainly short DNA fragments. In particular, I observed 
that in both of the 107 bp and 377 bp SRY assays, the relative concentrations of all 
except one cases were higher in the urine (median, 83.8% for the 107-bp SRY 
amplicon and 15.6% for the 377-bp amplicon) than in the plasma (median, 55.4% for 
the 107-bp SRY amplicon and 0.0% for the 377-bp amplicon). It showed that SRY, 
which represented donor-derived DNA from blood cells, were relatively longer in the 
urine than in the plasma. Moreover, the existence of SRYD]<\A molecule longer than 
377 bp in the urine but not in the plasma suggested a direct release of these 
high-moleculer weight DNA molecules from donor-dervied blood cells in the urine. 
For cases with female donors to male recipients, the size distribution of cell-free 
DNA in the plasma and the urine were summarized in Table 6.3B. In the plasma, I 
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observed that when the PCR amplicon size for LEP increased from 63 bp to 105 bp 
to 356 bp, its median concentrations, relative to the 63-bp amplicon, decreased from 
100% to 96.9% to 0% (median absolute concentration of LEP with the 63 bp assay 
was 594.1 GE/mL). This implied that the total, both donor- and recipient-derived, 
DNA molecules in cell-free plasma were mainly short DNA fragments. In the urine, I 
observed that when the PCR amplicon size for LEP increased from 63 bp to 105 bp 
to 356 bp, its median concentrations, relative to the 63-bp amplicon, similarly 
decreased from 100% to 83.3% to 1.8% (median absolute concentration of LEP with 
the 63 bp assay was 632.7 GE/mL). Thus, the total, both donor- and recipient-derived, 
DNA molecules in cell-free urine were also mainly short DNA fragments. In 
summary, the existence of more 356 bp LEP DNA molecules in the urine than in the 
plasma suggested a release of these high moleculer weight DNA into the urine from 
cellular portion of the urine. However, unlike the cases with female recipients 
receiving male stem cells, the LEP DNA molecular with 105 bp amplicon showed a 
higher median relative concentration in the plasma than in the urine (96.9% and 
83.3%, respectively). It might be due to increased level of apoptosis, which release 
small cell-free DNA fragments into plasma, in the donor-derived blood cells or solid 
organ of the recipients after HSCT. However, because the exact sources of these 
short LEP DNA molecules cannot be determined, it awaits further investigation to 
clearly address the sources of such increased release of LEP DNA. 
In the plasma, I observed that when the PCR amplicon size for SRY increased from 
63 bp to 107 bp to 377 bp, its median concentrations, relative to the 63-bp amplicon, 
decreased from 100% to 54.5% to 0% (median absolute concentration of SRY with 
the 63 bp assay was 103.4 GE/mL). This implied that the recipient-derived DNA 
molecules in cell-free plasma were mainly short DNA fragments. In the urine, I 
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observed that when the PCR amplicon size for SRY increased from 63 bp to 107 bp 
to 377 bp, its median concentrations, relative to the 63-bp amplicon, similarly 
decreased from 100% to 65.8% to 8.9% (median absolute concentration of SRY with 
the 63 bp assay was 647.12 GE/mL). Thus, the recipient-derived DNA molecules in 
cell-free urine were also mainly short DNA fragments. In particular, I observed that 
in both of the 107 bp and 377 bp 7 assays, the median relative concentrations were 
higher in the urine than that in the plasma. It showed that SRY, which represented 
recipient-derived DNA, were relatively longer in the urine than in the plasma. 
Moreover, the existence of SRY DNA molecule longer than 377 bp in the urine but 
not in the plasma suggested a direct release of these high-moleculer weight DNA 
from cellular portion of the urine. 
In summary, it could be observed that, in general, the sizes of cell-free DNA 
molecules, both LEP and SRY, in the urine were longer than those in the plasma. Of 
particular significance, the existence of SRY DNA molecules longer than 377 bp in 
urine, but not in plasma, of female recipients of male stem cells, suggested the direct 
release of these high-molecular weight DNA molecules into urine from 
donor-derived blood cells liberated into urine from the circulation. Similarly, the 
existence of SRY DNA molecules longer than 377 bp in urine, but not in plasma, of 
male recipients of female stem cells, suggested the direct release of these 
high-molecular weight DNA molecules into urine from recipient-derived cells 
liberated into urine from the urinary tract. 
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Table 6.2 Fractional concentrations of male DNA (%) in the plasma, urine and 
urine cell pellet of sex-mismatched HSCT recipients. 
Fractional concentration of male DNA (%) 
Sample Plasma Urine Urine cell pellet 
Male donor, female recipient 
BOOl 64.9 36.5 42.5 
B007 90.7 40.1 15.5 
B013 103.6 26.0 42.2 
B015 68.0 88.1 40.8 
Median 793 38.3 41.5 
Female donor，male recipient 
B003 30.4 78.1 40.7 
BOOS 27.2 70.8 41.6 
B009 0.0 92.3 83.7 
B016 23.0 88.8 90.6 
B025 71.3 108.0 101.0 
B026 35.2 111.1 84.5 
B028 26.0 102.3 94.6 
Median 2JU ^ 84.5 
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Table 6.3 Relative concentrations (%) of SRY and LEP DNA in the plasma and 
urine of sex-mismatched HSCT recipients. 
(A) Male donors, female recipients 
SRY ^ 
Amplicon size 63 bp 107 bp 377 bp 63 bp 105 bp 356 bp 
Plasma 
BOOl 100.0 30.0 0.0 100.0 68.9 0.0 
B007 100.0 64.1 0.0 100.0 63.1 0.0 
B013 100.0 46.6 0.0 100.0 36.0 64.2 
B015 100.0 109.3 9.2 100.0 38.3 44.5 
Median 100.0 55.4 0.0 100,0 50.7 22.3 
Urine 
BOOl 100.0 69.1 15.8 100.0 93.2 4.8 
B007 100.0 91.6 13.7 100.0 93.2 1.5 
B013 100.0 84.3 15.6 100.0 94.5 83.0 
B015 100.0 83.4 15.6 100.0 95.9 100.4 
Median 100.0 83.8 15.6 100,0 93,9 43.9 
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(B) Female donors, male recipients 
S^ LEP 
Amplicon size 63 bp 107 bp 377 bp 63 bp 105 bp 356 bp 
Plasma 
B003 100.0 88.7 0.0 100.0 70.2 0.0 
BOOS 100.0 0.0 0.0 100.0 96.9 0.0 
B009 100.0 0.0 0.0 100.0 81.4 0.0 
B016 100.0 54.5 0.0 100.0 107.1 0.0 
B025 100.0 55.0 0.0 100.0 97.9 0.0 
B026 100.0 49.9 0.0 100.0 118.1 1.2 
B028 100.0 123.9 0.0 100.0 89.8 1.6 
Median 100.0 54.5 0.0 100.0 96.9 0.0 
Urine 
B003 100.0 45.3 4.3 100.0 83.3 5.7 
BOOS 100.0 80.4 19.3 100.0 85.3 4.9 
B009 100.0 73.2 15.7 100.0 103.9 1.8 
B016 100.0 44.4 2.7 100.0 80.7 0.3 
B025 100.0 65.8 8.9 100.0 93.9 0.0 
B026 100.0 60.0 4.7 100.0 80.5 0.9 
B028 100.0 72.8 13.8 100.0 82.3 19.1 
Median 100.0 65,8 8.9 100.0 83.3 1.8 
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Figure 6.1 Standard curve of zinc finger protein gene assay on a series of 
artificial mixtures of male and female DNA. 
Plot of the measured fractional concentrations of male DNA (%) against expected 
fractional concentrations of male DNA (%). The correlation coefficient is 0.99. 
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Figure 6.2 Fractional concentrations of male DNA (%) in plasma and urine. 
Dot plots of fractional concentrations of male DNA in the plasma (A) and urine (B) 
of sex-mismatched HSCT patients. The genders of donors and recipients are shown 
on the X axis. The fractional concentration of the male DNA in the plasma is plotted 
on the y axis. The percentage of male DNA was generated using the zinc finger 
protein gene assay. 
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Figure 6.3 Fractional concentrations of male DNA (%) in sex-mis matched 
HSCT patients. 
(A) Correlation between fractional concentration of male DNA (%) in plasma and 
urine. (B) Correlation between fractional concentration of male DNA (%) in urine 
cell pellet and urine. 
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6.4 Discussion 
In this part of the thesis, I studied the different constituting components of cell-free 
DNA in the urine of HSCT recipients in the hope of providing technical and 
biological information on the use of these cell-free DNA, especially the Tr-DNA, in 
urine for noninvasive molecular tests. 
According to the Tr-DNA hypothesis (Botezatu et al 2000), Tr-DNA is downstream 
from cell-free DNA in plasma as it passes through the kidney barrier. Thus, only the 
more finely fragmented cell-free DNA in plasma can appear as Tr-DNA. In pregnant 
women, only a minor proportion (3.4%-6.2%) (Lo et al 1998b) of fetal cell-free 
DNA appears in maternal plasma. As fetal DNA passes the kidney barrier, its 
concentration further decreases as larger fragments were filtered. It might be the 
reason of the inability of some investigators to detect fetal DNA in urine of pregnant 
women (Zhong et al. 2001a, Li et al. 2003). In cancer patients, although the 
proportion of tumor-derived DNA in plasma is reasonably high, such chimerism 
varies a lot between different patients (Anker et al 1997). Thus, they might not be 
ideal models for studying the phenomenon of Tr-DNA. To address this problem, this 
study employed the sex-mismatched HSCT model which has higher levels and 
smaller range of fractional concentration of donor-derived DNA in plasma than fetal 
DNA is in maternal plasma (Lui et al. 2002). Thus, more donor-derived DNA is 
expected to pass into urine, which in turn, allows more robust detection. The 
implementation of this HSCT model has the potential to greatly improve current 
understandings on the phenomenon of Tr-DNA and the different cell-free 
components in the urine. 
To gain knowledge on the different constituting cell-free DNA components in urine, I 
143 
Cell-free DNA in urine 
Studied the fractional concentration of cell-free male DNA in the plasma, urine and 
urine cell pellets of these sex-mismached HSCT recipients. Size distributions of 
DNA molecules were also studied. It was found that a number of possible pathways 
may contribute to the cell-free DNA in urine (Figure 6.4). Firstly, it is the transrenal 
passage of cell-free DNA from the plasma into the urine, i.e. Tr-DNA. In female 
recipients of male stem cells, male DNA was present in both of the plasma and the 
urine of the recipients (Figure 6.2). Thus, it provided evidences to support for the 
presence of Tr-DNA. Secondly, it is the release of high-molecular weight DNA from 
blood cells liberated into the urine from the circulation. In female recipients of male 
stem cells, the existence of donor-derived SRYDIS^A molecules longer than 377 bp in 
urine but not in the plasma (Table 6.3A) suggested such a release of these 
high-molecular weight cell-free DNA from blood cells into the urine. Thirdly, it is 
the release of high-molecular weight DNA from cells liberated into the urine from 
the urinary tract, e.g. epithelial cells. Because in female recipients of male stem cells, 
the identity of DNA molecules released from the female urinary tract cannot be 
distinguished from that of the male donor. The third pathway was illustrated in male 
recipients of female stem cells, whose DNA from urinary tract is “male，’. In Table 
6.3B, the existence of recipient-derived SRY DNA molecules longer than 377 bp in 
urine but not in plasma suggested such a release of high-molecular weight cell-free 
DNA from cells liberated into the urine from the urinary tract. 
Summarizing the three mechanisms mentioned above，the transrenal passage of 
plasma cell-free DNA, cells from the hematopoietic system or the urinary tract are 
possible contributors of cell-free DNA in urine. To determine which mechanism is 
more prevalent in general, I performed correlation tests of the fractional 
concentrations of male DNA in the urine, urine cell pellets and plasma in these 
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sex-mismatched HSCT recipients. In these tests, a significant correlation is observed 
between the fractional concentrations in the cell-free urine and that in the urine cell 
pellets, but not between the fractional concentrations in the cell-free urine and the 
cell-free plasma. Therefore, I could deduce a dominant contribution of the cell-free 
DNA in urine from the cellular portion of urine. 
In summary, in this part of the thesis, I have used the HSCT model to study the 
constituting components of cell-free DNA in urine. It was found that the majority of 
cell-free DNA in urine was derived from cellular portion of the urine, which 
consisted of both donor- and recipient-derived cells. Moreover, it was shown that 
cell-free DNA in urine originated from hematopoietic cells in the circulation could be 
easily detected in urine using a PCR-based technology. Thus, this study provided 
fundamental information for the use of cell-free DNA in the urine for noninvasive 
clinical analysis. For example, cell-free DNA in the urine derived from blood cells 
can be used for noninvasive molecular analysis of hematological diseases and, 
cell-free DNA in urine derived from cells of the urinary tract may be used for 
noninvasive molecular analysis of any genetic diseases along the urinary tract. 
However, the sensitivity and clinical application of this new approach remain to be 
evaluated. 
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Figure 6.4 Schematic diagrams showing the three possible mechanisms resulting 
in the presence of cell-free DNA in the urine of HSCT recipients. 
(a) represents the transrenal passage of cell-free DNA from the plasma into the urine. 
(b) represents the release of high-molecular weight cell-free DNA from blood cells 
liberated into the urine from the circulation, (c) represents the release of 
high-molecular weight cell-free DNA from cells liberated into the urine from the 
urinary tract. 
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CHAPTER 7: CONCLUSION AND FUTURE PERSPECTIVES 
7.1 Circulating miRNA is a valuable resource for molecular analysis 
The discovery of placental mRNA transcripts in the plasma of pregnant women 
(Poon et al. 2000) has already opened up a new approach for noninvasive prenatal 
diagnosis (Ng et al 2003a, Ng et al 2003b). The recent discovery of miRNAs has 
prompted our team to investigate whether these small non-coding RNAs expressed in 
the placenta can also be detected in maternal plasma and be further developed as a 
novel class of circulating nucleic acids for molecular analysis. However, the 
existence and detection of miRNAs in human plasma has not been documented in the 
literature at the time of this writing. 
In the work described in this thesis, I have developed and evaluated a new 
methodology for the extraction and quantitative detection of miRNA in maternal 
plasma (Chapter 3 and Chapter 4). Using this methodology, I have provided the first 
demonstration in the presence of circulating miRNAs in cell-free maternal plasma 
(Chapter 4). In addition, since this methodology was based on absolute, rather than 
relative quantification, I have also been able to determine that some miRNAs in 
plasma can reach as high as 10^  copies per milliliter. These findings have revealed 
that miRNAs in plasma are stable enough for processing, extraction and can be 
robustly detected, and thus added a new and exciting dimension to the study of 
cell-free RNA species in plasma for noninvasive diagnosis and monitoring, not only 
for pregnancy, but also for other diseases and conditions. 
After the confirmation in the existence of circulating miRNA, Chapter 5 has 
described a systematic search for the discovery of placental miRNAs in maternal 
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plasma. This strategy does not only allow the identification of placental miRNA 
markers without prior knowledge of the miRNAs being studied, but also provides 
quantitative information about the miRNA present in maternal plasma. In brief, using 
this strategy, Chapter 5 has reported a list of 17 candidate placental miRNAs 
potentially detectable in maternal plasma. In one of the placental miRNAs, miR-141, 
it was shown that it was present in maternal plasma of the first trimester pregnancies 
and the level of plasma miR-141 was shown to correlate with the gestational age of 
pregnancies. It implies the possibility of using miR-141 for clinical analysis in as 
• til 
early as the first trimester (12 week) of pregnancy. These discoveries have opened 
up a completely new area of circulating pregnancy-specific miRNA markers for the 
potential applications in the diagnosis of pregnancy-associated disorders. Using this 
approach on other newly discovered miRNA, we should have a high chance of 
discovering other placental miRNAs for use in prenatal diagnosis. 
It is interesting to note the number of similarities and differences between circulating 
miRNAs and mRNA transcripts. Firstly, the use of circulating mRNAs as biomarkers 
have been considered superior to the detection of circulating DNA in terms of its 
much larger copy numbers. This would allow a higher sensitivity of detection in 
maternal plasma. The surprisingly higher level of miRNAs, compared with that of 
mRNA, might provide an even more sensitive detection. Secondly, circulating 
mRNAs and miRNAs are both stably present in maternal plasma for extraction and 
robust quantification. However, unlike placental mRNA which is associated with 
subcellular particles, placental miRNA in maternal plasma is not associated with 
subcellular particles. The stability of miRNA over mRNA in maternal plasma is 
likely a result of its extremely short sequence as demonstrated by its long lasting 
existence in plasma after incubation. Purified and non-protected placental miRNA, 
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when incubated in plasma with nuclease activities, showed a slower rate of 
degradation and stayed at higher levels afer 2 hours of incubation than mRNA 
transcripts. Further investigation would be needed to see whether miRNA is 
associated with biochemical molecules, such as lipid, ribosome and protein. These 
studies wil l enhance understanding of both the mechanism and biological 
significance behind the release of nucleic acids into plasma. 
In summary, this thesis has provided fundamental information and technical details 
on the potential application of a novel class of circulating nucleic acids, i.e. miRNA, 
in maternal plasma for noninvasive prenatal diagnostic tests. MiRNAs are stable and 
exist at very high concentration in plasma, enabling measurement with high precision. 
The biology and complex network of gene regulation by miRNAs also suggest the 
potential use of circulating miRNA for monitoring other diseases. For example, 
miRNA was found to be able to represent different cancer specifically. It is hopeful 
that future development in this field will enable a range of possible diagnostic tests 
based on circulating miRNAs. 
7.2 The presence of donor-derived DNA in the urine of HSCT recipients 
Apart from the cell-free nucleic acids in plasma, transrenal-DNA (Tr-DNA) in urine 
has recently attracted attention in its potential for noninvasive prenatal diagnosis. 
However, the detection of fetal DNA in urine cannot be reproduced by a number of 
groups (Zhong et al 2001a, Li et al. 2003) and the phenomenon is in itself poorly 
understood. Al l these have hindered the development of Tr-DNA for noninvasive 
prenatal diagnosis. To address this problem, Chapter 6 of this thesis has tried to 
elucidate the constitutive components of cell-free DNA in urine using 
sex-mismatched HSCT patients and, thus, to illustrate the potential use of cell-free 
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DNA in urine, such as Tr-DNA, for noninvasive diagnostic tests. We hope the HSCT 
system may serve as an established model to stimulate further innovative researches 
on the phenomenon of Tr-DNA and cell-free DNA in urine in uses of prenatal 
diagnosis and cancer detection. 
It is interesting to note that donor-derived DNA can be detected in the urine of these 
sex-mismatched HSCT patients. However, the data also suggested that cell-free DNA 
in the urine of HSCT patients had two possible sources: plasma cell-free DNA that 
has passed through the kidney barrier and high-molecular weight DNA that is 
released from the cellular portion of urine. The presence of high-molecular weight 
donor-derived and recipient-derived cell-free DNA in urine but not in plasma 
suggests the release of these DNA molecules from the cellular portion of urine. The 
correlation between the fractional concentrations of male DNA in urine and urine cell 
pellet has further suggested a dominant contribution of cell-free DNA in urine from 
cellular portion. 
In brief, this study has raised important considerations regarding the detection of 
Tr-DNA and other cell-free DNA in urine for clinical analysis. For example, because 
the high-molecular weight DNA released from the urinary tract is an important 
component of cell-free DNA in urine, quantitative detection of Tr-DNA in urine 
should be designed in such a way to facilitate the detection of the smaller Tr-DNA 
fraction in the future. Moreover, the presence of high-molecular weight DNA 
released from cells of the urinary tract in urine hints on the use of these DNA for 
molecular analysis of disease conditions along the urinary tract. In summary, this part 
of the thesis has provided important information and technical details for the 
detection of cell-free DNA in urine. These cell-free DNA molecules included both 
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donor-derived DNA and recipient-derived DNA. They are both potentially enabling 
new perspective in the use of these cell-free DNA for noninvasive diagnostic tests in 
the future. 
7.3 Prospects for future work 
The detection of cell-free nucleic acids in human bodily fluids, such as plasma and 
urine, offer numerous opportunities for noninvasive diagnostic investigations. Over 
the past few years, encouraging findings have been reported on the detection and 
possible clinical applications of cell-free nucleic acids. Further development in this 
field wil l be encouraged by a better understanding of the physiological and 
pathological characteristics of these circulating cell-free miRNA species and cell-free 
DNA in urine. 
In the first part of this thesis, I have investigated a systematic approach for 
identification of circulating placental miRNAs. Some of the molecular characteristics 
of these circulating miRNAs were also studied. One important future work is to 
investigate i f the aberrant plasma levels of these placental-derived miRNAs can be 
observed in pathological pregnancies. For example, a recent study performed by 
Pineles et al. (2007) demonstrated that a distinct subset of miRNAs is differentially 
expressed in the placentas of pregnancies with pre-eclampsia and 
small-for-gestational age fetuses. It would be useful to investigate if the aberration of 
these miRNAs expressed in the pathological placentas would also be reflected in 
maternal plasma. Further experimentation might be performed to look for plasma 
miRNAs whose levels are altered in these pathological conditions. This would 
represent another step forward to developing circulating miRNAs as markers for 
noninvasive prenatal diagnosis. On the other hand, with more advanced molecular 
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techniques and high throughput technologies, such as miRNA micro array, the 
number of miRNAs discovered in humans would continue to increase. It is of interest 
to apply this approach, which requires no prior knowledge of the function of 
miRNAs, as described in Chapter 5 to identify more circulating placental miRNAs. 
Finally, because miRNAs are important regulators of gene expression, further 
investigations might be conducted to address the question of whether circulating 
miRNA possesses any functional implication in terms of feto-matemal 
communication. 
In the latter part of this thesis, I have investigated in the constituting components of 
cell-free DNA in urine using HSCT patients to hint on the potential use of cell-free 
DNA in urine for diagnostic tests. It was found that the cell-free component consists 
of more than Tr-DNA. Conclusive evidence for presence of Tr-DNA requires further 
experimentation. In terms of future work, one might want to use techniques such as 
cell microscopy, flow cytometry and immunostaining to find out the cellular and 
genetic identities of cells in urine which contribute to majority of cell-free DNA in 
urine. Most importantly, after the establishment of the HSCT model for studying 
Tr-DNA, it would be worthwhile to study the different aspects of Tr-DNA, such as 
the mechanisms of formation and different biological and physical characteristic of 
Tr-DNA. It remains hopeful that the use of cell-free DNA in urine for molecular 




List of assay full names, target identities and sequences of TaqMan® MicroRNA 
Assays being employed in this thesis 
AB Assay ID miRNA Target Target Sequence 
abm000175 hsa-let-7a ugagguaguagguuguauaguu 
abm000176 hsa-let-7b ugagguaguagguugugugguu 
abm000177 hsa-let-7d agagguaguagguugcauagu 
abm000178 hsa-let-7e ugagguaggagguuguauagu 
abm000179 hsa-let-7g ugagguaguaguuuguacagu 
abm000180 hsa-let-7i ugagguaguaguuugugcu 
abm000046 hsa-miR-100 aacccguagauccgaacuugug 
abm000048 hsa-miR-103 agcagcauuguacagggcuauga 
abm000049 hsa-miR-104 ucaacaucagucugauaagcua 
abmOOOOSO hsa-miR-105 ucaaaugcucagacuccugu 
abm000051 hsa-miR-106a aaaagugcuuacagugcagguagc 
abm000053 hsa-miR-107 agcagcauuguacagggcuauca 
abm000004 hsa-miR-10a uacccuguagauccgaauuugug 
abm000054 hsa-miR-122a uggagugugacaaugguguuugu 
abm000055 hsa-miR-124a uuaaggcacgcggugaaugcca 
abm000056 hsa-miR-124b uuaaggcacgcggugaaugc 
abm000057 hsa-miR-125a ucccugagacccuuuaaccugug 
abm000058 hsa-miR-125b ucccugagacccuaacuuguga 
abm000059 hsa-miR-126 ucguaccgugaguaauaaugc 
abmOOOOeO hsa-miR-127 ucggauccgucugagcuuggcu 
abmOOOOei hsa-miR-128a ucacagugaaccggucucuuuu 
abm000062 hsa-miR-128b ucacagugaaccggucucuuuc 
abm000063 hsa-miR-129 cuuuuugcggucugggcuugc 
abm000064 hsa-miR-130a cagugcaauguuaaaagggc 
abm000065 hsa-miR-130b cagugcaaugaugaaagggcau 
abm000066 hsa-miR-132 uaacagucuacagccauggucg 
abm000067 hsa-miR-133a uugguccccuucaaccagcugu 
abm000068 hsa-miR-133b uugguccccuucaaccagcua 
abm000069 hsa-miR-134 ugugacugguugaccagaggg 
abm000070 hsa-miR-135a uauggcuuuuuauuccuauguga 
abm000071 hsa-miR-135b uauggcuuuucauuccuaugug 
abm000073 hsa-miR-137 uauugcuuaagaauacgcguag 
abm000074 hsa-miR-138 agcugguguugugaauc 
abm000075 hsa-miR-139 ucuacagugcacgugucu 
abm000076 hsa-miR-140 agugguuuuacccuaugguag 
abm000077 hsa-miR-141 aacacugucugguaaagaugg 
abm000078 hsa-miR-142-3p uguaguguuuccuacuuuaugga 
abm000079 hsa-miR-142-5p cauaaaguagaaagcacuac 
abm000081 hsa-miR-144 uacaguauagaugauguacuag 
abm000082 hsa-miR-145 guccaguuuucccaggaaucccuu 
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abm000083 hsa-miR-146 ugagaacugaauuccauggguu 
abm000084 hsa-miR-147 guguguggaaaugcuucugc 
abm000085 hsa-miR-148a ucagugcacuacagaacuuugu 
abm000087 hsa-miR-149 ucuggcuccgugucuucacucc 
abm000088 hsa-miR-150 ucucccaacccuuguaccagug 
abm000089 hsa-miR-151 acuagacugaagcuccuugagg 
abmOOOOQO hsa-miR-152 ucagugcaugacagaacuugg 
abm000092 hsa-miR-154 uagguuauccguguugccuucg 
abm000093 hsa-miR-154* aaucauacacgguugaccuauu 
abm000094 hsa-miR-155 uuaaugcuaaucgugauagggg 
abm000006 hsa-miR-15a uagcagcacauaaugguuugug 
abmOOOOO? hsa-miR-15b uagcagcacaucaugguuuaca 
abmOOOOOS hsa-miR-16 uagcagcacguaaauauuggcg 
abm000009 hsa-miR-17-3p acugcagugaaggcacuugu 
abmOOOOlO hsa-miR-17-5p caaagugcuuacagugcagguagu 
abm000095 hsa-miR-181a aacauucaacgcugucggugagu 
abm000096 hsa-miR-181b aacauucauugcugucgguggguu 
abm000097 hsa-miR-181c aacauucaaccugucggugagu 
abm000098 hsa-miR-182 uuuggcaaugguagaacucaca 
abm000099 hsa-miR-182* ugguucuagacuugccaacua 
abmOOOlOO hsa-miR-183 uauggcacugguagaauucacug 
abm000101 hsa-miR-184 uggacggagaacugauaagggu 
abmOOOl 02 hsa-miR-185 uggagagaaaggcaguuc 
abm000103 hsa-miR-186 caaagaauucuccuuuugggcuu 
abm000104 hsa-miR-187 ucgugucuuguguugcagccg 
abm000106 hsa-miR-189 gugccuacugagcugauaucagu 
abm000107 hsa-miR-190 ugauauguuugauauauuaggu 
abm000108 hsa-miR-191 caacggaaucccaaaagcagcu 
abm000109 hsa-miR-193 aacuggccuacaaagucccag 
abm000110 hsa-miR-194 uguaacagcaacuccaugugga 
abrnOOOm hsa-miR-195 uagcagcacagaaauauuggc 
abnn000112 hsa-miR-197 uucaccaccuucuccacccagc 
abmOOOH 3 hsa-miR-198 gguccagaggggagauagg 
abm000114 hsa-miR-199a cccaguguucagacuaccuguuc 
abm000115 hsa-miR-199a* uacaguagucugcacauugguu 
abm000116 hsa-miR-199b cccaguguuuagacuaucuguuc 
abmOOOUT hsa-miR-199-s cccaguguucagacuaccuguu 
abmOOOOH hsa-miR-19a ugugcaaaucuaugcaaaacuga 
abm000013 hsa-miR-20 uaaagugcuuauagugcaggua 
abm000118 hsa-miR-200a uaacacugucugguaacgaugu 
abm000119 hsa-miR-200b cucuaauacugccugguaaugaug 
abm000120 hsa-miR-200c aauacugccggguaaugaugga 
abm000121 hsa-miR-203 gugaaauguuuaggaccacuag 
abm000122 hsa-miR-204 uucccuuugucauccuaugccu 
abm000123 hsa-miR-205 uccuucauuccaccggagucug 
abm000014 hsa-miR-21 uagcuuaucagacugauguuga 
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abm000126 hsa-miR-210 cugugcgugugacagcggcug 
abm000127 hsa-miR-211 uucccuuugucauccuucgccu 
abm000128 hsa-miR-213 accaucgaccguugauuguacc 
abm000129 hsa-miR-214 acagcaggcacagacaggcag 
abm000130 hsa-miR-215 augaccuaugaauugacagac 
abm000131 hsa-miR-216 uaaucucagcuggcaacugug 
abm000133 hsa-miR-218 uugugcuugaucuaaccaugu 
abm000134 hsa-miR-219 ugauuguccaaacgcaauucu 
abm000135 hsa-miR-220 ccacaccguaucugacacuuu 
abm000136 hsa-miR-221 agcuacauugucugcuggguuuc 
abm000137 hsa-miR-222 agcuacaucuggcuacugggucuc 
abm000138 hsa-miR-223 ugucaguuugucaaauacccc 
abm000139 hsa-miR-224 caagucacuagugguuccguuua 
abm000016 hsa-miR-23a aucacauugccagggauuucc 
abm000017 hsa-miR-23b aucacauugccagggauuaccac 
abm000019 hsa-miR-25 cauugcacuugucucggucuga 
abm000020 hsa-miR-26a uucaaguaauccaggauaggcu 
abm000021 hsa-miR-26b uucaaguaauucaggauaggu 
abm000022 hsa-miR-27a uucacaguggcuaaguuccgcc 
abm000023 hsa-miR-27b uucacaguggcuaaguucug 
abm000024 hsa-miR-28 aaggagcucacagucuauugag 
abm000140 hsa-miR-296 agggcccccccucaauccugu 
abm000141 hsa-miR-299 ugguuuaccgucccacauacau 
abm000025 hsa-miR-29a cuagcaccaucugaaaucgguu 
abm000026 hsa-miR-29b uagcaccauuugaaaucagu 
abm000027 hsa-miR-29c uagcaccauuugaaaucgguua 
abm000142 hsa-miR-301 cagugcaauaguauugucaaagc 
abm000143 hsa-miR-302a uaagugcuuccauguuuugguga 
abm000144 hsa-miR-302b uaagugcuuccauguuuuaguag 
abm000145 hsa-miR-302b* acuuuaacauggaagugcuuucu 
abm000146 hsa-miR-302c uaagugcuuccauguuucagugg 
abm000147 hsa-miR-302c* uuuaacauggggguaccugcug 
abm000148 hsa-miR-302d uaagugcuuccauguuugagugu 
abm000028 hsa-miR-30a-3p cuuucagucggauguuugcagc 
abm000029 hsa-miR-30b uguaaacauccuacacucagc 
abmOOOOSO hsa-miR-30c uguaaacauccuacacucucagc 
abmOOOOSI hsa-miR-30d uguaaacauccccgacuggaag 
abm000032 hsa-miR-SOe uguaaacauccuugacugga 
abm000033 hsa-miR-31 ggcaagaugcuggcauagcug 
abm000149 hsa-miR-320 aaaagcuggguugagagggcgaa 
abm000151 hsa-miR-323 gcacauuacacggucgaccucu 
abm000153 hsa-miR-324-5p cgcauccccuagggcauuggugu 
abm000154 hsa-miR-325 ccuaguagguguccaguaagu 
abm000155 hsa-miR-326 ccucugggcccuuccuccag 
abm000156 hsa-miR-328 cuggcccucucugcccuuccgu 
abm000157 hsa-miR-330 gcaaagcacacggccugcagaga 
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abm000158 hsa-miR-331 gccccugggccuauccuagaa 
abm000159 hsa-miR-335 ucaagagcaauaacgaaaaaugu 
abm000160 hsa-miR-337 uccagcuccuauaugaugccuuu 
abm000161 hsa-miR-338 uccagcaucagugauuuuguuga 
abm000162 hsa-miR-339 ucccuguccuccaggagcuca 
abm000163 hsa-miR-340 uccgucucaguuacuuuauagcc 
abm000164 hsa-miR-342 ucucacacagaaaucgcacccguc 
abm000036 hsa-miR-34a uggcagugucuuagcugguugu 
abm000037 hsa-miR-34b aggcagugucauuagcugauug 
abmOOOOSS hsa-miR-34c aggcaguguaguuagcugauug 
abm000166 hsa-miR-367 aauugcacuuuagcaaugguga 
abm000167 hsa-miR-368 acauagaggaaauuccacguuu 
abm000169 hsa-miR-370 gccugcugggguggaaccugg 
abm000170 hsa-miR-371 gugccgccaucuuuugagugu 
abm000171 hsa-miR-372 aaagugcugcgacauuugagcgu 
abm000172 hsa-miR-373 gaagugcuucgauuuuggggugu 
abm000173 hsa-miR-373* acucaaaaugggggcgcuuucc 
abm000174 hsa-miR-374 uuauaauacaaccugauaagug 
abm001112 hsa-miR-515-5p uucuccaaaagaaagcacuuucug 
abm001157 hsa-miR-518c caaagcgcuucucuuuagagug 
abm001169 hsa-miR-520d ucuacaaagggaagcccuuucug 
abm001175 hsa-miR-526b cucuugagggaagcacuuucuguu 
abm000002 hsa-miR-9 ucuuugguuaucuagcuguauga 
abmOOOOOS hsa-miR-9* uaaagcuagauaaccgaaagu 
abm000039 hsa-miR-92 uauugcacuugucccggccugu 
abm000041 hsa-miR-95 uucaacggguauuuauugagca 
abm000042 hsa-miR-96 uuuggcacuagcacauuuuugc 
abm000043 hsa-miR-98 ugagguaguaaguuguauuguu 
abm000044 hsa-miR-99a aacccguagauccgaucuugug 
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